API




KE Relationships

Navigational tip: click on "leads to" or the ID column to navigate to the KE Relationship.
Id Upstream Event Relationship Type Downstream Event
5 Reduction, 17beta-estradiol synthesis by ovarian granulosa cells leads to Reduction, Plasma 17beta-estradiol concentrations
9 Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity leads to Decreased, Mitochondrial fatty acid beta-oxidation
750 Activation, 5HT2c leads to N/A, Unknown
454 Accumulation, Acetylcholine in synapses leads to Increased, Atrioventricular block and bradycardia
456 Accumulation, Acetylcholine in synapses leads to Induction, Ataxia, paralysis, or hyperactivity
459 Accumulation, Acetylcholine in synapses leads to Inhibition, Acetylcholinesterase (AchE)
11 Inhibition, Acetylcholinesterase (AchE) leads to Accumulation, Acetylcholine in synapses
449 Inhibition, Acetylcholinesterase (AchE) leads to Increased, Atrioventricular block and bradycardia
450 Inhibition, Acetylcholinesterase (AchE) leads to Increased, Respiratory distress/arrest
451 Inhibition, Acetylcholinesterase (AchE) leads to Induction, Ataxia, paralysis, or hyperactivity
452 Inhibition, Acetylcholinesterase (AchE) leads to Increased, Mortality
453 Inhibition, Acetylcholinesterase (AchE) leads to Decreased, Population trajectory
16 Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways leads to Altered, Cardiovascular development/function
17 Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways leads to Up Regulation, CYP1A1
18 Activation, AhR leads to Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways
19 Activation, AhR leads to Up Regulation, CYP1A1
869 Activation, AhR leads to Induction, CYP1A2/CYP1A5
1656 Activation, AhR leads to Up Regulation, SCD-1
972 Activation, AhR leads to dimerization, AHR/ARNT
984 Activation, AhR leads to Increase, Early Life Stage Mortality
473 Activation, AhR leads to Inhibition, Mitochondrial fatty acid beta-oxidation
495 Activation, AhR leads to Up Regulation, CD36
496 Activation, AhR leads to Increased, FA Influx
499 Activation, AhR leads to Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)
506 Activation, AhR leads to Up Regulation, LDLR (low density lipoprotein receptor)
509 Activation, AhR leads to Suppression, VLDL secretion
31 Agonism, Androgen receptor leads to Reduction, Gonadotropins, circulating concentrations
32 Agonism, Androgen receptor leads to Reduction, Testosterone synthesis by ovarian theca cells
1384 Agonism, Androgen receptor leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
1385 Agonism, Androgen receptor leads to Reduction, Vitellogenin synthesis in liver
33 N/A, Androgen receptor, Antagonism leads to Decreased, Transcription of genes by AR
35 N/A, Androgen receptor, Antagonism leads to Alteration, Wnt pathway
36 Reduction, Angiogenesis leads to Impairment, Endothelial network
43 Decrease, Aromatase (Cyp19a1) leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
45 Inhibition, Aromatase leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
1767 Inhibition, Aromatase leads to Altered regulation, Alpha hemoglobin
51 Induction, Ataxia, paralysis, or hyperactivity leads to Decrease, Population trajectory
434 Induction, Ataxia, paralysis, or hyperactivity leads to Increased, Mortality
457 Induction, Ataxia, paralysis, or hyperactivity leads to Increased, Respiratory distress/arrest
1601 Decrease, Mitochondrial ATP production leads to Decrease, Oogenesis
1670 Decrease, Mitochondrial ATP production leads to Decrease, Leaf cell mitosis
1682 Decrease, Mitochondrial ATP production leads to Increase, Cytotoxicity (renal tubular cell)
1739 Decrease, Mitochondrial ATP production leads to Growth
1750 Decrease, Mitochondrial ATP production leads to Increase, Apoptosis
927 Inhibition, Bile Salt Export Pump (ABCB11) leads to Bile accumulation, Pathological condition
59 Reduction, Ca and HCO3 transport to shell gland leads to Reduction, Eggshell thickness
60 Increase, Ca++ (intracellular) leads to Disruption, Mitochondrial electron transport chain
61 Inhibition, Ca++ ATPase leads to Increase, Ca++ (intracellular)
62 Decreased, Calcium influx leads to Impairment, Learning and memory
347 Decreased, Calcium influx leads to BDNF, Reduced
66 Up Regulation, CD36 leads to Increase, FA Influx
501 Up Regulation, CD36 leads to Increased, FA Influx
67 N/A, Cell injury/death leads to Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
68 N/A, Cell injury/death leads to Activation, Stellate cells
355 N/A, Cell injury/death leads to Synaptogenesis, Decreased
364 N/A, Cell injury/death leads to N/A, Neurodegeneration
365 N/A, Cell injury/death leads to N/A, Neuroinflammation
1688 N/A, Cell injury/death leads to Neuronal network function, Decreased
924 N/A, Cell injury/death leads to Release, Cytokine
1718 N/A, Cell injury/death leads to Tissue resident cell activation
69 Proliferation, Cell proliferation in the absence of cytotoxicity leads to Hyperplasia, Hyperplasia
70 Induction, Chitin degradation and resorption leads to Induction, Pre-mature molting
667 Reduction, Ionotropic GABA receptor chloride channel conductance leads to Reduction, Neuronal synaptic inhibition
77 Activation, ChREBP leads to Synthesis, De Novo FA
483 Activation, ChREBP leads to Increased, De Novo FA synthesis
82 Accumulation, Collagen leads to N/A, Liver fibrosis
1629 Accumulation, Collagen leads to Pulmonary fibrosis
88 N/A, Covalent binding to protein, possibly lysine residue leads to Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways
1700 N/A, Covalent binding to protein, possibly lysine residue leads to Activation, Dendritic Cells
93 Production, Critical Metabolites (CGA 330050 and CGA 265307) leads to Induction, Liver “Dysfunctional” Changes by CGA 330050
94 Reduction, Cumulative fecundity and spawning leads to Decrease, Population trajectory
95 Inhibition, Cyclooxygenase activity leads to Reduction, Prostaglandin E2 concentration
670 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandin F2alpha synthesis, ovary
681 Inhibition, Cyclooxygenase activity leads to Decreased, Prostaglandin F2alpha synthesis, ovary
686 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandins, ovary
689 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandin E2 concentration, hypothalamus
96 Up Regulation, CYP1A1 leads to Peptide Oxidation
104 Up Regulation, CYP1B1 leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
108 Release, Cytokine leads to Increase, Inflammation
925 Release, Cytokine leads to Infiltration, Inflammatory cytokines
994 Release, Cytokine leads to Infiltration, Inflammatory cells
110 Synthesis, De Novo FA leads to Accumulation, Triglyceride
23 Alkylation, DNA leads to Increase, Heritable mutations in offspring
24 Alkylation, DNA leads to N/A, Insufficient or incorrect DNA repair
25 Alkylation, DNA leads to Increase, Mutations
901 Alkylation, DNA leads to Increase, Cancer
1343 Increase, EcR agonism leads to Increase, E75b expression
116 Increase, EcR agonism leads to Induction, Chitin degradation and resorption
998 Increase, EcR agonism leads to Decrease, Circulating ETH
999 Increase, EcR agonism leads to Decreased, synthesis and secretion of molting fluid proteases
1007 Increase, EcR agonism leads to Decreased, Synthesis of molting fluid proteases
123 Reduction, Eggshell thickness leads to N/A, Reproductive failure
125 Impairment, Endothelial network leads to Insufficiency, Vascular
976 Impairment, Endothelial network leads to Altered, Cardiovascular development/function
126 Agonism, Estrogen receptor leads to Altered, Reproductive behaviour
127 Agonism, Estrogen receptor leads to Impaired development of, Reproductive organs
128 Agonism, Estrogen receptor leads to Increase, Vitellogenin synthesis in liver
129 Antagonism, Estrogen receptor leads to Reduction, Vitellogenin synthesis in liver
132 Increase, FA Influx leads to Accumulation, Triglyceride
133 Activation, FAS leads to Synthesis, De Novo FA
1422 Activation, FAS leads to Increased, lipogenesis
136 N/A, Gap leads to Reduction, Ca and HCO3 transport to shell gland
385 Activation, Glucocorticoid Receptor leads to Induction, IKB inhibitory protein
1451 Activation, Glucocorticoid Receptor leads to Reduced, BDNF
143 Reduction, Gonadotropins, circulating concentrations leads to Reduction, Testosterone synthesis by ovarian theca cells
144 Depletion, GSH leads to N/A, Oxidative stress
146 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) leads to Peptide Oxidation
147 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) leads to Up Regulation, TGFbeta1 expression
996 N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects leads to Alterations, Cellular proliferation / hyperplasia
154 Decreased, HSD17B10 expression leads to Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity
158 Hyperplasia, Hyperplasia leads to Promotion, Hepatocelluar carcinoma
386 Induction, IKB inhibitory protein leads to Inhibition, Nuclear factor kappa B (NF-kB)
159 Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 leads to Induction, Sustained Hepatotoxicity
781 Increase, Inflammation leads to Increase, Regenerative cell proliferation (forestomach epithelial cells)
929 Increase, Inflammation leads to Cholestasis, Pathology
1722 Increase, Inflammation leads to Expression of Collagen
1724 Increase, Inflammation leads to EMT
1699 Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways leads to Activation, Dendritic Cells
388 Suppression, Inflammatory cytokines leads to Decreased, Lymphocytes
164 N/A, Insufficient or incorrect DNA repair leads to Increase, Mutations
168 N/A, Interferences with SH-/selen-proteins leads to Depletion, GSH
169 Increase, Liver and splenic hemosiderosis leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
170 Induction, Liver “Dysfunctional” Changes by CGA 330050 leads to Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307
874 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Changes/Inhibition, Cellular Homeostasis and Apoptosis
875 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Alterations, Cellular proliferation / hyperplasia
876 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Formation, Hepatocellular and Bile duct tumors
172 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
516 Activation, LXR leads to Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)
173 Activation, LXR leads to Up Regulation, CD36
174 Activation, LXR leads to Activation, ChREBP
175 Activation, LXR leads to Activation, FAS
176 Activation, LXR leads to Activation, SCD-1
177 Activation, LXR leads to Activation, SREBP-1c
479 Activation, LXR leads to Activation, SREBF1
490 Activation, LXR leads to Up Regulation, FAS
491 Activation, LXR leads to Up Regulation, SCD-1
510 Activation, LXR leads to Inhibition, PPAR alpha
389 Decreased, Lymphocytes leads to Increased, Disease susceptibility
390 Decreased, Lymphocytes leads to Suppression, Immune system
182 N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number leads to N/A, Cyanosis occurs
1367 Damaging, Mitochondria leads to Apoptosis
1311 N/A, Mitochondrial dysfunction 1 leads to Altered, Ca2+-calmodulin activated signal transduction
582 N/A, Mitochondrial dysfunction 1 leads to Neuronal network function, Decreased
363 N/A, Mitochondrial dysfunction 1 leads to N/A, Cell injury/death
1152 N/A, Mitochondrial dysfunction 1 leads to impaired, Hive thermoregulation
1154 N/A, Mitochondrial dysfunction 1 leads to Weakened, Colony
904 N/A, Mitochondrial dysfunction 1 leads to Impaired, Proteostasis
908 N/A, Mitochondrial dysfunction 1 leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
660 N/A, Mitochondrial dysfunction 1 leads to Overwhelmed, Mitochondrial DNA repair mechanisms
1684 N/A, Mitochondrial dysfunction 1 leads to Oxidative Stress
664 N/A, Mitochondrial dysfunction 1 leads to impaired, Thoracic shivering
188 Disruption, Mitochondrial electron transport chain leads to Decrease, Mitochondrial ATP production
189 Disruption, Mitochondrial electron transport chain leads to Increase, ROS production
617 Decreased, Mitochondrial fatty acid beta-oxidation leads to Increased, Liver Steatosis
190 Decreased, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid
1025 Abnormal, Morphogenesis leads to Increased, Developmental Defects
196 Abnormal, Morphogenesis leads to Increased, Lethality
197 Abnormal, Morphogenesis leads to Increased, Structural malformations
899 Increase, Mutations leads to Increase, Cancer
202 Increase, Mutations leads to Increase, Heritable mutations in offspring
203 Altered, Neuroanatomy leads to Altered, Neurophysiology
906 N/A, Neuroinflammation leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
1687 N/A, Neuroinflammation leads to N/A, Cell injury/death
208 N/A, Neuroinflammation leads to N/A, Neurodegeneration
759 N/A, Neuroinflammation leads to Synaptogenesis, Decreased
210 N/A, Neuronal dysfunction leads to N/A, Neuroinflammation
384 Altered, Neurophysiology leads to Cognitive Function, Decreased
212 Decreased, Nitric Oxide leads to Decreased, Long-term potentiation (LTP)
213 Inhibition, NMDARs leads to Decreased, Calcium influx
214 Inhibition, NMDARs leads to Impairment, Learning and memory
215 Inhibition, NMDARs leads to N/A, Neuronal dysfunction
228 Binding of antagonist, NMDA receptors leads to Impairment, Learning and memory
229 Binding of antagonist, NMDA receptors leads to Inhibition, NMDARs
387 Inhibition, Nuclear factor kappa B (NF-kB) leads to Suppression, Inflammatory cytokines
1379 Peptide Oxidation leads to Activation, JNK
922 Peptide Oxidation leads to N/A, Mitochondrial dysfunction 1
923 Peptide Oxidation leads to Release, Cytokine
1698 Peptide Oxidation leads to S-Glutathionylation, eNOS
932 Peptide Oxidation leads to Cholestasis, Pathology
948 Peptide Oxidation leads to Oxidation, Glutathione
1467 Peptide Oxidation leads to Increase, DNA Damage
980 Peptide Oxidation leads to Decrease, GTPCH-1
1237 Peptide Oxidation leads to Increase activation, Nuclear factor kappa B (NF-kB)
992 Peptide Oxidation leads to Decrease, AKT/eNOS activity
236 Peptide Oxidation leads to Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
764 Peptide Oxidation leads to Increase, Adenomas/carcinomas (hepatocellular)
765 Peptide Oxidation leads to Increase, Cytotoxicity
239 N/A, Oxidative stress leads to N/A, Neuronal dysfunction
240 Propagation, Oxidative stress leads to Down Regulation, Gulcose-6-phosphate dehydrogenase
241 Propagation, Oxidative stress leads to Damaging, Red blood cells; hemolysis
242 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Altered regulation, Alpha hemoglobin
243 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Formation, Formation of hemoglobin adducts
244 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Propagation, Oxidative stress
245 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Damaging, Red blood cells; hemolysis
928 Bile accumulation, Pathological condition leads to Release, Cytokine
930 Bile accumulation, Pathological condition leads to Production, Reactive oxygen species
248 Bile accumulation, Pathological condition leads to Activation of specific nuclear receptors, Transcriptional change
503 Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) leads to Accumulation, Fatty acid
1386 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Plasma vitellogenin concentrations
392 Reduction, Plasma 17beta-estradiol concentrations leads to irregularities, ovarian cycle
252 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Vitellogenin synthesis in liver
253 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
254 Increase, Plasma vitellogenin concentrations leads to Increase, Renal pathology due to VTG deposition
1769 Reduction, Plasma vitellogenin concentrations leads to Reduction, Cumulative fecundity and spawning
255 Reduction, Plasma vitellogenin concentrations leads to Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
535 Activation, PPARα leads to Activation, LXR alpha
369 Activation, PPARα leads to Decrease, Steroidogenic acute regulatory protein (STAR)
370 Activation, PPARα leads to Decrease, Translocator protein (TSPO)
1410 Activation, PPARα leads to Activation, HSD17B4
1229 Activation, PPARα leads to modulation, Genes/proteins that regulate hepatocyte fate
1233 Activation, PPARα leads to Increase, Genes involved in fatty acid oxidation
1236 Activation, PPARα leads to Activation, NADPH Oxidase
256 demethylation, PPARg promoter leads to Decrease, Aromatase (Cyp19a1)
1608 demethylation, PPARg promoter leads to Activation of specific nuclear receptors, PPAR-gamma activation
1402 demethylation, PPARg promoter leads to Activation, SREBP-1
1659 demethylation, PPARg promoter leads to Increased, FA Influx
395 demethylation, PPARg promoter leads to reduction in ovarian granulosa cells, Aromatase (Cyp19a1)
1424 demethylation, PPARg promoter leads to Activation, FAS
411 demethylation, PPARg promoter leads to Up Regulation, CD36
487 demethylation, PPARg promoter leads to Activation, SREBF1
257 Decreased, PPAR-alpha activation leads to Decreased, HSD17B10 expression
259 Decreased, PPAR-beta activation leads to Decreased, HSD17B10 expression
260 Decreased, PPAR-gamma activation leads to Decreased, HSD17B10 expression
261 Induction, Pre-mature molting leads to Decrease, Fecundity
262 Induction, Pre-mature molting leads to Increase, Mortality
263 Induction, Pre-mature molting leads to Increased, Mortality
266 Feminisation or incomplete development, Primary and accessory male sex organs leads to N/A, Impairment of reproductive capacity
268 Reduction, Prostaglandin E2 concentration leads to N/A, Gap
269 Alkylation, Protein leads to N/A, Cell injury/death
271 Alkylation, Protein leads to Peptide Oxidation
1680 Alkylation, Protein leads to Dysfunction, Mitochondria
518 Activation, PXR/SXR leads to Inhibition, FoxA2
526 Activation, PXR/SXR leads to Up Regulation, SCD-1
529 Activation, PXR/SXR leads to Up Regulation, CD36
272 Increase, RBC congestion in liver leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
276 Production, Reactive oxygen species leads to Peptide Oxidation
931 Production, Reactive oxygen species leads to Cholestasis, Pathology
277 Damaging, Red blood cells; hemolysis leads to Increase, Liver and splenic hemosiderosis
278 Damaging, Red blood cells; hemolysis leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
279 Damaging, Red blood cells; hemolysis leads to Increase, RBC congestion in liver
280 Increase, Renal pathology due to VTG deposition leads to Altered, Larval development
282 Increase, ROS production leads to Decreased, Nitric Oxide
283 Increase, ROS production leads to Increased, Oxidative damage
1602 Increase, ROS production leads to Increase, DNA Damage
1603 Increase, ROS production leads to Increase, Lipid peroxidation
1623 Increase, ROS production leads to Increased, secretion of local growth factors
912 Increase, ROS production leads to N/A, Mitochondrial dysfunction 1
1754 Increase, ROS production leads to Increase, Uncoupling of OXPHOS
284 Activation, SCD-1 leads to Synthesis, De Novo FA
1404 Activation, SCD-1 leads to Increased, lipogenesis
287 Binding, SH-/selen-proteins leads to N/A, Interferences with SH-/selen-proteins
294 Activation, SREBP-1c leads to Synthesis, De Novo FA
295 Activation, Stellate cells leads to Accumulation, Collagen
436 Decrease, Steroidogenic acute regulatory protein (STAR) leads to Reduction, Cholesterol transport in mitochondria
298 Induction, Sustained Cell Proliferation leads to Formation, Liver tumor
299 Induction, Sustained Hepatotoxicity leads to Induction, Sustained Cell Proliferation
301 Activation/Proliferation, T-cells leads to N/A, Allergic contact dermatitis on challenge
835 Activation/Proliferation, T-cells leads to sensitisation, skin
1701 Activation/Proliferation, T-cells leads to Increase, Allergic Respiratory Hypersensitivity Response
302 Reduction, Testosterone synthesis by ovarian theca cells leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
303 Up Regulation, TGFbeta1 expression leads to Accumulation, Collagen
304 Up Regulation, TGFbeta1 expression leads to Activation, Stellate cells
809 TH synthesis, Decreased leads to Decreased, Thyroxine (T4) in serum
810 TH synthesis, Decreased leads to Increased, Serum creatinine
305 TH synthesis, Decreased leads to T4 in serum, Decreased
1504 TH synthesis, Decreased leads to BDNF, Reduced
1505 TH synthesis, Decreased leads to GABAergic interneurons, Decreased
1506 TH synthesis, Decreased leads to Impairment, Learning and memory
1768 TH synthesis, Decreased leads to Reduction, Plasma 17beta-estradiol concentrations
1040 Thyroperoxidase, Inhibition leads to Reduced, Anterior swim bladder inflation
790 Thyroperoxidase, Inhibition leads to Decrease, Incorporation of active iodide into iodotyrosines
309 Thyroperoxidase, Inhibition leads to TH synthesis, Decreased
366 Thyroperoxidase, Inhibition leads to T4 in serum, Decreased
383 Thyroperoxidase, Inhibition leads to Cognitive Function, Decreased
444 T4 in neuronal tissue, Decreased leads to BDNF, Reduced
746 T4 in neuronal tissue, Decreased leads to Hippocampal gene expression, Altered
1039 T4 in serum, Decreased leads to Reduced, Anterior swim bladder inflation
312 T4 in serum, Decreased leads to T4 in neuronal tissue, Decreased
1387 T4 in serum, Decreased leads to Hippocampal gene expression, Altered
1388 T4 in serum, Decreased leads to Hippocampal anatomy, Altered
1389 T4 in serum, Decreased leads to Hippocampal Physiology, Altered
1143 T4 in serum, Decreased leads to Decreased, Thyroxine (T4) in tissues
403 T4 in serum, Decreased leads to Cognitive Function, Decreased
315 Reduction, Vitellogenin synthesis in liver leads to Reduction, Plasma vitellogenin concentrations
316 Decreased, Transcription of genes by AR leads to Feminisation or incomplete development, Primary and accessory male sex organs
317 Decreased, Transcription of genes by AR leads to Alteration, Wnt pathway
319 Activation of specific nuclear receptors, Transcriptional change leads to Cholestasis, Pathology
399 Decrease, Translocator protein (TSPO) leads to Reduction, Testosterone synthesis in Leydig cells
437 Decrease, Translocator protein (TSPO) leads to Reduction, Cholesterol transport in mitochondria
321 Accumulation, Triglyceride leads to Damaging, Mitochondria
474 Accumulation, Triglyceride leads to Accumulation, Liver lipid
324 N/A, Unknown leads to Proliferation, Cell proliferation in the absence of cytotoxicity
751 N/A, Unknown leads to Increased, Kidney Failure
1036 Insufficiency, Vascular leads to Increased, Developmental Defects
329 Insufficiency, Vascular leads to Abnormal, Morphogenesis
330 Binding, VEGF-A leads to Decreased, VegfR2
331 Binding, VEGF-A leads to Inhibition, VegfR2
332 Production, VEGF-A leads to Binding, VEGF-A
333 Production, VEGF-A leads to Decreased, VegfR2
334 Decreased, VegfR2 leads to Inhibition, VegfR2
335 Inhibition, VegfR2 leads to Reduction, Angiogenesis
336 Increase, Vitellogenin synthesis in liver leads to Increase, Plasma vitellogenin concentrations
337 Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development leads to Reduction, Cumulative fecundity and spawning
338 Alteration, Wnt pathway leads to Feminisation or incomplete development, Primary and accessory male sex organs
1567 Altered, Cardiovascular development/function leads to Increase, Early Life Stage Mortality
1352 Altered, Cardiovascular development/function leads to Increase, Mortality
977 Altered, Cardiovascular development/function leads to Increase, Pericardial edema
514 Accumulation, Fatty acid leads to Increased, Triglyceride formation
515 Accumulation, Fatty acid leads to Increased, Liver Steatosis
472 Accumulation, Fatty acid leads to Accumulation, Triglyceride
502 Accumulation, Fatty acid leads to Accumulation, Liver lipid
135 Decrease, Fecundity leads to Decline, Population
1472 Decrease, Fertility leads to Decrease, Population trajectory
564 Impairment, Learning and memory leads to Abnormal, Roll change within caste
583 Impairment, Learning and memory leads to Abnormal, Foraging activity and behavior
1644 Impairment, Learning and memory leads to Decreased, locomotion
405 Malformation, Male reproductive tract leads to impaired, Fertility
198 Increase, Mortality leads to Decrease, Fecundity
199 Increase, Mortality leads to Decline, Population
1004 Increase, Mortality leads to Decreased, population 1
1013 Increase, Mortality leads to Decreased, Population size
1191 Increased, Mortality leads to Decreased, Population size
428 Increased, Mortality leads to Decreased, Population trajectory
200 Increased, Mortality leads to Decline, Population
756 Increased, Mortality leads to Decreased, population 1
1069 N/A, Neurodegeneration leads to Impairment, Learning and memory
368 N/A, Neurodegeneration leads to Neuronal network function, Decreased
647 N/A, Neurodegeneration leads to Decreased, Neuronal network function in adult brain
207 N/A, Neurodegeneration leads to N/A, Neuroinflammation
1265 Decline, Population leads to Alteration, Food-web structures
296 Increased, Structural malformations leads to Increased, Lethality
548 Formation, Pro-mutagenic DNA Adducts leads to Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts
551 Formation, Pro-mutagenic DNA Adducts leads to Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
344 Formation, Pro-mutagenic DNA Adducts leads to Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
345 Formation, Pro-mutagenic DNA Adducts leads to Tumorigenesis, Hepatocellular carcinoma
352 Formation, Pro-mutagenic DNA Adducts leads to Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
549 Increased, Induced Mutations in Critical Genes leads to Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
342 Increased, Induced Mutations in Critical Genes leads to Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
346 Increased, Induced Mutations in Critical Genes leads to Tumorigenesis, Hepatocellular carcinoma
351 Increased, Induced Mutations in Critical Genes leads to Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
891 Increased, Induced Mutations in Critical Genes leads to Increase, Site of Contact Nasal Tumors
343 Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H leads to Tumorigenesis, Hepatocellular carcinoma
340 Activation, Pre-MIE: Metabolism of AFB1 leads to Formation, Pro-mutagenic DNA Adducts
348 BDNF, Reduced leads to Aberrant, Dendritic morphology
353 BDNF, Reduced leads to N/A, Cell injury/death
354 BDNF, Reduced leads to Reduced, Presynaptic release of glutamate
870 BDNF, Reduced leads to GABAergic interneurons, Decreased
445 BDNF, Reduced leads to Down Regulation, K-Cl co-transporter 2 (KCC2)
448 BDNF, Reduced leads to Synaptogenesis, Decreased
1507 BDNF, Reduced leads to Impairment, Learning and memory
356 Aberrant, Dendritic morphology leads to Synaptogenesis, Decreased
357 Reduced, Presynaptic release of glutamate leads to Synaptogenesis, Decreased
350 Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci leads to Tumorigenesis, Hepatocellular carcinoma
358 Synaptogenesis, Decreased leads to Neuronal network function, Decreased
656 Synaptogenesis, Decreased leads to N/A, Neuroinflammation
359 Neuronal network function, Decreased leads to Impairment, Learning and memory
360 Binding of agonist, NMDARs leads to Overactivation, NMDARs
361 Overactivation, NMDARs leads to Increased, Intracellular Calcium overload
362 Increased, Intracellular Calcium overload leads to N/A, Mitochondrial dysfunction 1
892 Increased, Intracellular Calcium overload leads to Decreased, Neuronal network function in adult brain
833 Covalent Binding, Protein leads to Activation, Keratinocytes
376 Covalent Binding, Protein leads to Response, Keratinocytes
377 Covalent Binding, Protein leads to Activation, Dendritic Cells
378 Response, Keratinocytes leads to Activation, Dendritic Cells
380 Response, Keratinocytes leads to Activation/Proliferation, T-cells
379 Activation, Dendritic Cells leads to Activation/Proliferation, T-cells
570 Suppression, Immune system leads to Increased, Viral susceptibility
393 irregularities, ovarian cycle leads to Decrease, Fertility
394 irregularities, ovarian cycle leads to impaired, Fertility
396 reduction in ovarian granulosa cells, Aromatase (Cyp19a1) leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
402 Metabolism of AFB1, Production of Reactive Electrophiles leads to Formation, Pro-mutagenic DNA Adducts
439 Reduction, Testosterone synthesis in Leydig cells leads to Reduction, testosterone level
461 Increase, Luteinizing hormone (LH) leads to Increase proliferation, Leydig cell
462 Hyperplasia, Leydig cell leads to impaired, Fertility
398 Increase proliferation, Leydig cell leads to Hyperplasia, Leydig cell
552 Inhibition, Na+/I- symporter (NIS) leads to TH synthesis, Decreased
442 Inhibition, Na+/I- symporter (NIS) leads to Thyroidal Iodide, Decreased
1503 Inhibition, Na+/I- symporter (NIS) leads to Impairment, Learning and memory
872 Thyroidal Iodide, Decreased leads to TH synthesis, Decreased
443 Thyroidal Iodide, Decreased leads to T4 in serum, Decreased
811 Decreased, Thyroxine (T4) in serum leads to Occurrence, Cytoplasmic vacuolization (Renal tubule)
812 Decreased, Thyroxine (T4) in serum leads to Occurrence, Cystic dilatation (renal tubule)
815 Decreased, Thyroxine (T4) in serum leads to Occurrence, Cytoplasmic vacuolization (podocyte)
446 Down Regulation, K-Cl co-transporter 2 (KCC2) leads to Delay, Developmental GABA shift
447 Delay, Developmental GABA shift leads to Synaptogenesis, Decreased
1491 Decreased, Population trajectory leads to Increased, Mortality
591 Increased, Atrioventricular block and bradycardia leads to Increased, Respiratory distress/arrest
432 Increased, Atrioventricular block and bradycardia leads to Increased, Mortality
592 Increased, Respiratory distress/arrest leads to N/A, hypoxia
433 Increased, Respiratory distress/arrest leads to Increased, Mortality
608 Reduction, testosterone level leads to Malformation, Male reproductive tract
1649 Reduction, testosterone level leads to Decreased sperm quantity or quality in the adult, Decreased fertility
460 Reduction, testosterone level leads to Increase, Luteinizing hormone (LH)
438 Reduction, Cholesterol transport in mitochondria leads to Reduction, Testosterone synthesis in Leydig cells
471 Suppression, VLDL secretion leads to Accumulation, Liver lipid
538 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Increased, Liver Steatosis
470 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Liver lipid
475 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid
486 Increased, Triglyceride formation leads to Increased, Liver Steatosis
476 Suppression, Constitutive androstane receptor, NR1l3 leads to Activation, LXR
477 Suppression, Constitutive androstane receptor, NR1l3 leads to demethylation, PPARg promoter
1662 Activation, SREBF1 leads to Increased, Liver Steatosis
482 Activation, SREBF1 leads to Increased, De Novo FA synthesis
489 Activation, SREBF1 leads to Up Regulation, SCD-1
512 Increased, De Novo FA synthesis leads to Accumulation, Fatty acid
1607 Increased, De Novo FA synthesis leads to Increased, Liver Steatosis
484 Increased, De Novo FA synthesis leads to Increased, Triglyceride formation
1695 Increased, Liver Steatosis leads to Increased, Reactive oxygen species
1657 Up Regulation, SCD-1 leads to Accumulation, Triglyceride
493 Up Regulation, SCD-1 leads to Increased, Triglyceride formation
492 Up Regulation, FAS leads to Increased, De Novo FA synthesis
1658 Increased, FA Influx leads to Increased, Triglyceride formation
504 Increased, FA Influx leads to Accumulation, Triglyceride
505 Increased, FA Influx leads to Accumulation, Fatty acid
507 Up Regulation, LDLR (low density lipoprotein receptor) leads to Increased, LDL uptake
508 Increased, LDL uptake leads to Accumulation, Fatty acid
511 Inhibition, PPAR alpha leads to Inhibition, Mitochondrial fatty acid beta-oxidation
517 Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) leads to Increased, De Novo FA synthesis
519 Inhibition, FoxA2 leads to Down Regulation, CPT1A
523 Inhibition, FoxA2 leads to Down Regulation, HMGCS2
520 Down Regulation, CPT1A leads to Decreased, Mitochondrial fatty acid beta-oxidation
524 Down Regulation, HMGCS2 leads to Decreased, Ketogenesis
1660 Decreased, Ketogenesis leads to Accumulation, Fatty acid
532 Activation, NRF2 leads to Activation, NR1H4
1406 Activation, NRF2 leads to Activation, FXR
533 Activation, NR1H4 leads to Activation, SHP
534 Activation, NR1H4 leads to Activation, PPARα
896 Activation, SHP leads to Inhibition, SREBP1c
1409 Activation, SHP leads to Activation, PPARα
1412 Activation, SHP leads to Inhibition, LXR
1414 Activation, SHP leads to Inhibition, LRH-1
537 Decreased, DHB4/HSD17B4 leads to Inhibition, Mitochondrial fatty acid beta-oxidation
1606 Activation, LXR alpha leads to Increased, De Novo FA synthesis
1661 Activation, AKT2 leads to Activation, SREBF1
541 inflammation leads to Activation, AKT2
544 Decrease, Ovulation leads to Reduction, Cumulative fecundity and spawning
687 Decrease, Ovulation leads to Reduced, Reproductive Success
1471 Decrease, Ovulation leads to Decrease, Fertility
1753 Decrease, Ovulation leads to Decrease, Fecundity
550 Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) leads to Tumorigenesis, Hepatocellular carcinoma
547 Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts leads to Increased, Induced Mutations in Critical Genes
1645 GR Agonist, Activation leads to Increased apoptosis, decreased Leydig Cells
1646 GR Agonist, Activation leads to Repressed expression of steroidogenic enzymes
1648 Repressed expression of steroidogenic enzymes leads to Reduction, Testosterone synthesis in Leydig cells
1647 Increased apoptosis, decreased Leydig Cells leads to Reduction, Testosterone synthesis in Leydig cells
1650 Decreased sperm quantity or quality in the adult, Decreased fertility leads to impaired, Fertility
581 Activation, Nicotinic acetylcholine receptor leads to N/A, Mitochondrial dysfunction 1
1146 Activation, Nicotinic acetylcholine receptor leads to Impairment, Learning and memory
1147 Activation, Nicotinic acetylcholine receptor leads to Abnormal, Foraging activity and behavior
658 Activation, Nicotinic acetylcholine receptor leads to Desensitization, Nicotinic acetylcholine receptor
569 Abnormal, Foraging activity and behavior leads to Decrease, Number of worker bees
584 Abnormal, Foraging activity and behavior leads to Reduced, Food storage
1144 Abnormal, Foraging activity and behavior leads to Weakened, Colony
1148 Abnormal, Foraging activity and behavior leads to Abnormal, Roll change within caste
1150 Abnormal, Foraging activity and behavior leads to Abnormal, Role change within caste
558 Reduced, Food storage leads to Decrease, Number of worker bees
562 Reduced, Food storage leads to impaired, Larval development
565 Abnormal, Roll change within caste leads to Reduced, Brood care
579 Abnormal, Roll change within caste leads to Reduced, Food storage
580 Abnormal, Roll change within caste leads to Decrease, Number of worker bees
1149 Abnormal, Roll change within caste leads to Weakened, Colony
566 Reduced, Brood care leads to impaired, Larval development
563 impaired, Larval development leads to Death/Failure, Colony
574 impaired, Hive thermoregulation leads to Death/Failure, Colony
1153 impaired, Hive thermoregulation leads to Weakened, Colony
662 Accumulation, Damaged mitochondrial DNA leads to Accelerated, Aging
663 Accelerated, Aging leads to Decrease, Number of worker bees
559 Decrease, Number of worker bees leads to Death/Failure, Colony
573 Decrease, Number of worker bees leads to impaired, Hive thermoregulation
567 Increase, Energetic demands and therefore metabolic stress leads to Increased, Appetite and hunger
568 Increased, Appetite and hunger leads to Abnormal, Foraging activity and behavior
571 Increased, Viral susceptibility leads to impaired, Development
575 Increased, Viral susceptibility leads to Abnormal, Foraging activity and behavior
572 impaired, Development leads to Decrease, Number of worker bees
576 Decreased, Glucose oxidase enzyme activity leads to Decreased, Hydrogen peroxide production
577 Decreased, Hydrogen peroxide production leads to Reduced, Antiseptic incorporated in food
578 Reduced, Antiseptic incorporated in food leads to Abnormal, Roll change within caste
665 impaired, Thoracic shivering leads to impaired, Hive thermoregulation
585 Inhibition, sodium channel leads to Decreased, Sodium conductance 1
590 Inhibition, sodium channel leads to Increased, Atrioventricular block and bradycardia
1242 Inhibition, sodium channel leads to Decreased, sodium conductance 2
586 Decreased, Sodium conductance 1 leads to Reduced, swimming speed
594 Decreased, Sodium conductance 1 leads to Increased, Atrioventricular block and bradycardia
587 Reduced, swimming speed leads to Reduced, feeding 1
588 Reduced, swimming speed leads to Increased, predation
589 Reduced, feeding 1 leads to Increased, predation
596 Reduced, feeding 1 leads to Reduced, survival
595 Increased, predation leads to Reduced, survival
654 Increased, predation leads to Decreased, survival
593 N/A, hypoxia leads to Increased, amputations
597 Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel leads to Decreased, Sodium conductance 1
603 modulation, sodium channel leads to prolonged, Depolarization of neuronal membrane
604 prolonged, Depolarization of neuronal membrane leads to Overactivation, Neuronotransmitter release
605 Overactivation, Neuronotransmitter release leads to Overactivation, muscle contraction
606 Overactivation, muscle contraction leads to Increased, Ataxia, paralysis, or hyperactivity
607 Increased, Ataxia, paralysis, or hyperactivity leads to Increased, Mortality
630 Occurrence, A paroxysmal depolarizing shift leads to Occurrence, Epileptic seizure
634 Decreased, Neuronal network function in adult brain leads to Impairment, Learning and memory
1316 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, muscular waves in foot
1317 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, valve movement
1318 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increase, cilia movement
1319 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to increased mantel display
1337 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, oocyte maturation
635 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, serotonin (5-HT) 1
643 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, serotonin (5-HT)
1208 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, cilia movement
636 Increased, serotonin (5-HT) 1 leads to Increase, cilia movement
640 Increased, serotonin (5-HT) 1 leads to Increased, muscular waves in foot
1172 Increased, serotonin (5-HT) 1 leads to Increased, valve movement
1186 Increased, serotonin (5-HT) 1 leads to Decreased, gametogenesis
1189 Increased, serotonin (5-HT) 1 leads to Increased, locomotion
1192 Increased, serotonin (5-HT) 1 leads to increased or inappropriate, mantel display
1321 Increase, cilia movement leads to induced spawning
1335 Increase, cilia movement leads to Induced parturition
637 Increase, cilia movement leads to Increased, locomotion
639 Increase, cilia movement leads to Increased, foot detachment
1178 Increase, cilia movement leads to premature, spawning 1
1187 Increase, cilia movement leads to premature, Spawning
1217 Increase, cilia movement leads to Increased, water pumping
1218 Increase, cilia movement leads to Depletion, energy reserves
638 Increased, locomotion leads to Increase, predation
1177 Increased, locomotion leads to Depletion, energy reserves
1184 Increase, predation leads to Decline, Population
1176 Increased, foot detachment leads to Depletion, energy reserves
1183 Increased, foot detachment leads to Increase, predation
641 Increased, muscular waves in foot leads to Increased, locomotion
642 Increased, muscular waves in foot leads to Increased, foot detachment
1228 Increased, muscular waves in foot leads to Depletion, energy reserves
1327 Increased, serotonin (5-HT) leads to Increased, valve movement
1332 Increased, serotonin (5-HT) leads to Increased, muscular waves in foot
1333 Increased, serotonin (5-HT) leads to Increase, cilia movement
1336 Increased, serotonin (5-HT) leads to increased mantel display
644 Increased, serotonin (5-HT) leads to Decreased, anxiety
1207 Increased, serotonin (5-HT) leads to Increased, mantel display
1209 Increased, serotonin (5-HT) leads to Increased, cilia movement
1212 Increased, serotonin (5-HT) leads to Increased, oocyte maturation
645 Decreased, anxiety leads to Decreased, sheltering
646 Decreased, sheltering leads to Increased, predation
1643 Decrease, histaminergic neuron excitation leads to Impairment, Learning and memory
649 Decrease, histaminergic neuron excitation leads to N/A, sedation
650 N/A, sedation leads to Decreased, locomotion
651 Decreased, locomotion leads to Increased, predation
1061 Antagonism, Histamine Receptor (H2) leads to Decrease, histaminergic neuron excitation
1309 Desensitization, Nicotinic acetylcholine receptor leads to Altered, Ca2+-calmodulin activated signal transduction
659 Desensitization, Nicotinic acetylcholine receptor leads to Neuronal network function, Decreased
661 Overwhelmed, Mitochondrial DNA repair mechanisms leads to Accumulation, Damaged mitochondrial DNA
666 Binding at picrotoxin site, iGABAR chloride channel leads to Reduction, Ionotropic GABA receptor chloride channel conductance
683 Reduction, Neuronal synaptic inhibition leads to Generation, Amplified excitatory postsynaptic potential (EPSP)
672 Reduced, Prostaglandin F2alpha concentration, plasma leads to Reduced, Spawning behavior
678 Reduced, Prostaglandin F2alpha concentration, plasma leads to Reduced, Pheromone release
671 Reduced, Prostaglandin F2alpha synthesis, ovary leads to Reduced, Prostaglandin F2alpha concentration, plasma
673 Reduced, Spawning behavior leads to Reduced, Ability to attract spawning mates
674 Reduced, Ability to attract spawning mates leads to Reduced, Reproductive Success
675 Reduced, Reproductive Success leads to Decrease, Population trajectory
679 Reduced, Pheromone release leads to Reduced, Ability to attract spawning mates
682 Decreased, Prostaglandin F2alpha synthesis, ovary leads to Reduced, Prostaglandin F2alpha concentration, plasma
684 Generation, Amplified excitatory postsynaptic potential (EPSP) leads to Occurrence, A paroxysmal depolarizing shift
685 Reduced, Prostaglandins, ovary leads to Decrease, Ovulation
690 Reduced, Prostaglandin E2 concentration, hypothalamus leads to Reduced, Gonadotropin releasing hormone, hypothalamus
691 Reduced, Gonadotropin releasing hormone, hypothalamus leads to Reduced, Luteinizing hormone (LH), plasma
692 Reduced, Luteinizing hormone (LH), plasma leads to Reduced, Maturation inducing steroid, plasma
693 Reduced, Maturation inducing steroid, plasma leads to Reduced, Maturation inducing steroid receptor signalling, oocyte
694 Reduced, Maturation inducing steroid receptor signalling, oocyte leads to Increased, cyclic adenosine monophosphate
698 Reduced, Maturation inducing steroid receptor signalling, oocyte leads to Upregulated, Spindle assembly checkpoint protein Mad2-oocyte
695 Increased, cyclic adenosine monophosphate leads to Reduced, Reproductive Success
696 Increased, cyclic adenosine monophosphate leads to Reduced, Meiotic prophase I/metaphase I transition, oocyte
697 Reduced, Meiotic prophase I/metaphase I transition, oocyte leads to Reduced, Reproductive Success
699 Upregulated, Spindle assembly checkpoint protein Mad2-oocyte leads to Increased, Chromosome misseggregation
700 Increased, Chromosome misseggregation leads to Reduced, Reproductive Success
701 impaired, ion channels leads to Altered, Action Potential
702 Altered, Action Potential leads to Increased, cardiac arrthymia
703 Increased, cardiac arrthymia leads to Increased, Mortality
707 Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) leads to Increase, Cytotoxicity (renal tubular cell)
1676 Increase, Cytotoxicity (renal tubular cell) leads to Occurrence, Kidney toxicity
708 Increase, Cytotoxicity (renal tubular cell) leads to Increase, Regenerative cell proliferation (tubular epithelial cells)
785 Increase, Regenerative cell proliferation (tubular epithelial cells) leads to Increase, Hyperplasia (tubular epithelial cells)
760 Increase, Regenerative cell proliferation (tubular epithelial cells) leads to Increase, Hyperplasia (renal tubular cells)
706 Increased, Binding of chemicals to 2u (serum) leads to Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)
711 Activation, Constitutive androstane receptor leads to Increase, Mitogenic cell proliferation (hepatocytes)
1268 Activation, Constitutive androstane receptor leads to Altered expression of hepatic CAR-dependent genes
773 Increase, Mitogenic cell proliferation (hepatocytes) leads to Increase, Preneoplastic foci (hepatocytes)
1239 Increase, Mitogenic cell proliferation (hepatocytes) leads to Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
714 Binding, Tubulin leads to Depolymerization, Microtubule
724 Binding, Tubulin leads to Altered, Chromosome number
715 Depolymerization, Microtubule leads to Disorganization, Spindle
737 Disorganization, Spindle leads to Altered, Meiotic chromosome dynamics
723 Altered, Chromosome number leads to Increase, Aneuploid offspring
716 Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme leads to Increased, Induction of pyruvate dehydrogenase (PDH)
762 Increased, Induction of pyruvate dehydrogenase (PDH) leads to Increase, Oxidative metabolism
726 Increase, Necrosis (terminal bronchiolar cells) leads to Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)
727 Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) leads to Increase, Hyperplasia (terminal bronchiolar cells)
728 Increase, Hyperplasia (terminal bronchiolar cells) leads to Increase, Adenomas/carcinomas (bronchioloalveolar)
768 Decreased, Uptake of inorganic iodide leads to Decrease, Serum thyroid hormone (T4/T3)
742 Increase, Hypertrophy and proliferation (follicular cell) leads to Increase, Hyperplasia (follicular cells)
743 Increase, Hyperplasia (follicular cells) leads to Increase, Adenomas/carcinomas (follicular cell)
729 Decreased, Androgen receptor activity leads to Decreased, Testosterone binding to androgen receptor (hypothalamus)
730 Decreased, Testosterone binding to androgen receptor (hypothalamus) leads to Increase, Hyperplasia (Leydig cells)
744 Decreased, Testosterone binding to androgen receptor (hypothalamus) leads to Increased, Luteinizing hormone (LH)
731 Increase, Hyperplasia (Leydig cells) leads to Increase, Leydig cell tumors
770 Increase, Dopaminergic activity leads to Increase, Endometrial adenocarcinomas
732 Increase, Dopaminergic activity leads to Decreased, Prolactin
733 Decreased, Prolactin leads to Increased, Estrogen receptor (ER) activity
734 Increased, Estrogen receptor (ER) activity leads to Decreased, Progesterone from corpus luteum
772 Decreased, Progesterone from corpus luteum leads to Increase, Hyperplasia (glandular epithelial cells of endometrium)
738 Altered, Meiotic chromosome dynamics leads to Altered, Chromosome number
741 Increase, Thyroid-stimulating hormone (TSH) leads to Increase, Hypertrophy and proliferation (follicular cell)
745 Increased, Luteinizing hormone (LH) leads to Increase, Hyperplasia (Leydig cells)
747 Hippocampal gene expression, Altered leads to Hippocampal anatomy, Altered
749 Hippocampal anatomy, Altered leads to Hippocampal Physiology, Altered
748 Hippocampal Physiology, Altered leads to Cognitive Function, Decreased
752 Activation, Glutamate-gated chloride channel leads to Increased, Chloride conductance
1052 Increased, Chloride conductance leads to Increased, Neuronal synaptic inhibition
758 Increased, Chloride conductance leads to hyperpolarisation, neuron
1051 Activation, ionotropic GABA Receptor chloride channel leads to Increased, Chloride conductance
1566 hyperpolarisation, neuron leads to Analgesia
1572 hyperpolarisation, neuron leads to Anti-depressant Activity
755 hyperpolarisation, neuron leads to N/A, Ataxia, paralysis, or hyperactivity
757 N/A, Ataxia, paralysis, or hyperactivity leads to Increased, Mortality
775 Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme leads to Increased, Plasma tyrosine
761 Increase, Hyperplasia (renal tubular cells) leads to Increase, Adenomas/carcinomas (renal tubular)
887 Increase, Cytotoxicity leads to Increase, Tissue Degeneration, Necrosis & Atrophy
766 Increase, Cytotoxicity leads to Increase, Adenomas/carcinomas (hepatocellular)
763 Increase, Oxidative metabolism leads to Peptide Oxidation
767 Increase, Cytotoxicity (club cells) leads to Increase, Necrosis (terminal bronchiolar cells)
769 Decrease, Serum thyroid hormone (T4/T3) leads to Increase, Thyroid-stimulating hormone (TSH)
771 Increase, Hyperplasia (glandular epithelial cells of endometrium) leads to Increase, Endometrial adenocarcinomas
774 Increase, Preneoplastic foci (hepatocytes) leads to Increase, Adenomas/carcinomas (hepatocellular)
776 Increased, Plasma tyrosine leads to Increase, Cytotoxicity (corneal cells)
777 Increase, Cytotoxicity (corneal cells) leads to Increase, Inflammation (corneal cells)
778 Increase, Inflammation (corneal cells) leads to Increase, Regenerative cell proliferation (corneal cells)
779 Increase, Regenerative cell proliferation (corneal cells) leads to Increase, Papillomas/carcinomas (squamous cells)
780 Increase, Cytotoxicity (epithelial cells) leads to Increase, Inflammation
782 Increase, Regenerative cell proliferation (forestomach epithelial cells) leads to Increase, Hyperplasia (forestomach epithelial cells)
783 Increase, Hyperplasia (forestomach epithelial cells) leads to Increase, Papillomas/carcinomas (squamous cells)
784 Increase, Cytotoxicity (tubular epithelial cells) leads to Increase, Regenerative cell proliferation (tubular epithelial cells)
786 Increase, Hyperplasia (tubular epithelial cells) leads to Increase, Adenomas/carcinomas (renal tubular)
787 Activation, Androgen receptor leads to Increase, Mitogenic cell proliferation (hepatocytes)
788 Increase, Cytotoxicity (hepatocytes) leads to Increase, Regenerative cell proliferation (hepatocytes)
789 Increase, Regenerative cell proliferation (hepatocytes) leads to Increase, Preneoplastic foci (hepatocytes)
791 Decrease, Incorporation of active iodide into iodotyrosines leads to Decrease, Serum thyroid hormone (T4/T3)
792 Inhibition, 5α-reductase activity leads to Decrease, Bioactivation of testosterone
794 Increased, Leutinizing hormone (LH) leads to Increase, Hyperplasia (Leydig cells)
793 Decrease, Bioactivation of testosterone leads to Increased, Leutinizing hormone (LH)
795 Increase, Urinary bladder calculi leads to Increase, Cytotoxicity (urothelial cells)
796 Increase, Cytotoxicity (urothelial cells) leads to Increase, Regenerative cell proliferation (urothelial cells)
797 Increase, Regenerative cell proliferation (urothelial cells) leads to Increase, Hyperplasia (urothelial)
798 Increase, Hyperplasia (urothelial) leads to Increase, Adenomas/carcinomas (urothelial)
799 Inhibition, Prolyl hydroxylases leads to Increased, HIF-1 heterodimer
800 Increased, HIF-1 heterodimer leads to Decreased, Aromatase (Cyp19a1) mRNA
801 Decreased, Aromatase (Cyp19a1) mRNA leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
802 modulation, Unknown leads to Increased, HIF-1 alpha transcription
803 Increased, HIF-1 alpha transcription leads to Increased, HIF-1 heterodimer
804 Inhibition, HMG-CoA reductase leads to Decreased, mevalonate
805 Decreased, mevalonate leads to Decreased, cholesterol
806 Decreased, cholesterol leads to Decreased, Testosterone
807 Decreased, Testosterone leads to malformed, Male reproductive tract
808 malformed, Male reproductive tract leads to Decrease, Fertility
813 Increased, Serum creatinine leads to Occurrence, Cytoplasmic vacuolization (Renal tubule)
814 Increased, Serum creatinine leads to Occurrence, Cystic dilatation (renal tubule)
816 Increased, Serum creatinine leads to Occurrence, Cytoplasmic vacuolization (podocyte)
817 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Glomerular filtration
818 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Renal plasma flow
819 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Sodium reabsorption
820 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Renal ability to dilute urine
829 Decreased, Glomerular filtration leads to Occurrence, Kidney toxicity
830 Decreased, Renal plasma flow leads to Occurrence, Kidney toxicity
831 Decreased, Sodium reabsorption leads to Occurrence, Kidney toxicity
821 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Glomerular filtration
822 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Renal plasma flow
823 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Sodium reabsorption
824 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Renal ability to dilute urine
825 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Glomerular filtration
826 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Renal plasma flow
827 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Sodium reabsorption
828 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Renal ability to dilute urine
832 Decreased, Renal ability to dilute urine leads to Occurrence, Kidney toxicity
834 Activation, Keratinocytes leads to Activation, Dendritic Cells
836 Inhibition, Phospholipase A leads to Damage, Lipid bilayer
837 Inhibition, Phospholipase A leads to Disturbance, Lysosomal function
838 Inhibition, Phospholipase A leads to Injury, Mitochondria
839 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
840 Damage, Lipid bilayer leads to Occurrence, Ballooning degeneration (hepatocyte)
841 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
842 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
843 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
844 Disturbance, Lysosomal function leads to Occurrence, Ballooning degeneration (hepatocyte)
845 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
846 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
1678 Disturbance, Lysosomal function leads to Disruption, Lysosome
847 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
848 Injury, Mitochondria leads to Occurrence, Ballooning degeneration (hepatocyte)
849 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
850 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
851 Occurrence, Cytoplasmic vacuolization (hepatocyte) leads to Induction, Microvesicular fat
852 Occurrence, Cytoplasmic vacuolization (hepatocyte) leads to Formation, Mallory body
853 Occurrence, Ballooning degeneration (hepatocyte) leads to Induction, Microvesicular fat
854 Occurrence, Ballooning degeneration (hepatocyte) leads to Formation, Mallory body
855 Occurrence, Cytoplasmic vacuolization (Bile duct cell) leads to Induction, Microvesicular fat
856 Occurrence, Cytoplasmic vacuolization (Bile duct cell) leads to Formation, Mallory body
857 Occurrence, Cytoplasmic vacuolization (kupffer cell) leads to Induction, Microvesicular fat
858 Occurrence, Cytoplasmic vacuolization (kupffer cell) leads to Formation, Mallory body
859 Induction, Microvesicular fat leads to Formation, Liver fibrosis
860 Formation, Mallory body leads to Formation, Liver fibrosis
864 Oxidation, Uroporphyrinogen leads to Accumulation, Highly carboxylated porphyrins
865 Oxidation, Uroporphyrinogen leads to Inhibition, UROD
1070 Inhibition, UROD leads to Accumulation, Highly carboxylated porphyrins
867 Inhibition, UROD leads to Oxidation, Uroporphyrinogen
866 Accumulation, Highly carboxylated porphyrins leads to Uroporphyria
868 Induction, CYP1A2/CYP1A5 leads to Oxidation, Uroporphyrinogen
871 GABAergic interneurons, Decreased leads to Synaptogenesis, Decreased
995 Changes/Inhibition, Cellular Homeostasis and Apoptosis leads to N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
997 Alterations, Cellular proliferation / hyperplasia leads to Formation, Hepatocellular and Bile duct tumors
877 Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain leads to Decreased, PPARalpha transactivation of gene expression
878 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
879 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
880 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Ketogenesis (production of ketone bodies)
1748 Decreased, PPARalpha transactivation of gene expression leads to Fatty Acid Beta Oxidation, Decreased
881 Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
882 Decreased, Mitochondrial Fatty Acid Beta Oxidation leads to Decreased, Ketogenesis (production of ketone bodies)
883 Decreased, Ketogenesis (production of ketone bodies) leads to Not Increased, Circulating Ketone Bodies
884 Not Increased, Circulating Ketone Bodies leads to Increased, Catabolism of Muscle Protein
885 Increased, Catabolism of Muscle Protein leads to Decreased, Body Weight
886 Decrease, Intracellular pH leads to Increase, Cytotoxicity
888 Increase, Tissue Degeneration, Necrosis & Atrophy leads to Increase, Respiratory or Squamous Metaplasia
889 Increase, Respiratory or Squamous Metaplasia leads to Increase, Cell Proliferation
890 Increase, Cell Proliferation leads to Increased, Induced Mutations in Critical Genes
893 Increase, Cell Proliferation leads to Increase, Mutations in Critical Genes
895 Increase, Cell Proliferation leads to Increase, Site of Contact Nasal Tumors
919 Binding of agonist, Ionotropic glutamate receptors leads to Overactivation, NMDARs
894 Increase, Mutations in Critical Genes leads to Increase, Site of Contact Nasal Tumors
1131 Inhibition, organic anion transporter 1 (OAT1) leads to Increased, blood uric acid concentration
934 Inhibition, NADH-ubiquinone oxidoreductase (complex I) leads to N/A, Mitochondrial dysfunction 1
933 Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) leads to Inhibition, NADH-ubiquinone oxidoreductase (complex I)
905 Impaired, Proteostasis leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
907 Degeneration of dopaminergic neurons of the nigrostriatal pathway leads to N/A, Neuroinflammation
910 Degeneration of dopaminergic neurons of the nigrostriatal pathway leads to Parkinsonian motor deficits
911 Disruption, Lysosome leads to Increase, ROS production
1679 Disruption, Lysosome leads to Increase, Cytotoxicity (renal tubular cell)
921 Disruption, Lysosome leads to Peptide Oxidation
993 Disruption, Lysosome leads to N/A, Mitochondrial dysfunction 1
916 Infiltration, Inflammatory cells leads to Inflammation, Liver
926 Infiltration, Inflammatory cytokines leads to Inflammation, Liver
936 Activation, Epidermal Growth Factor Receptor leads to Decrease, Apoptosis of ciliated epithelial cells
939 Activation, Epidermal Growth Factor Receptor leads to Increase, Proliferation of goblet cells
942 Activation, Epidermal Growth Factor Receptor leads to Occurrence, Transdifferentiation of ciliated epithelial cells
946 Activation, Epidermal Growth Factor Receptor leads to Activation, Sp1
961 Decrease, Apoptosis of ciliated epithelial cells leads to Occurrence, Transdifferentiation of ciliated epithelial cells
943 Occurrence, Transdifferentiation of ciliated epithelial cells leads to Occurrence, Metaplasia of goblet cells
1313 Occurrence, Metaplasia of goblet cells leads to Increase, Mucin production
990 Occurrence, Metaplasia of goblet cells leads to Hypersecretion, Mucus
1312 Goblet cell hyperplasia leads to Increase, Mucin production
989 Goblet cell hyperplasia leads to Hypersecretion, Mucus
944 Increase, Proliferation of goblet cells leads to Goblet cell hyperplasia
987 Activation, Sp1 leads to Increase, Mucin production
954 Oxidation, Glutathione leads to S-Glutathionylation, eNOS
955 S-Glutathionylation, eNOS leads to Uncoupling, eNOS
956 Uncoupling, eNOS leads to Depletion, Nitric Oxide
958 Depletion, Nitric Oxide leads to Impaired, Vasodilation
953 Decrease, Tetrahydrobiopterin leads to Uncoupling, eNOS
952 Decrease, GTPCH-1 leads to Decrease, Tetrahydrobiopterin
982 Impaired, Vasodilation leads to Increase, Vascular Resistance
962 Activation, EGFR leads to Decrease, Apoptosis of ciliated epithelial cells
964 Activation, EGFR leads to Activation, Sp1
965 Activation, EGFR leads to Occurrence, Transdifferentiation of ciliated epithelial cells
970 Activation, EGFR leads to Increase, Proliferation of goblet cells
986 Activation, EGFR leads to Increase, Mucin production
1350 dimerization, AHR/ARNT leads to Increase, COX-2 expression
973 dimerization, AHR/ARNT leads to reduced dimerization, ARNT/HIF1-alpha
974 reduced dimerization, ARNT/HIF1-alpha leads to reduced production, VEGF
975 reduced production, VEGF leads to Impairment, Endothelial network
983 Increase, Vascular Resistance leads to Hypertension
1315 Increase, Mucin production leads to Chronic, Mucus hypersecretion
991 Increase, Mucin production leads to Hypersecretion, Mucus
988 Decrease, AKT/eNOS activity leads to Depletion, Nitric Oxide
1062 Formation, The binding of FK506 with FKBP12 leads to Inhibition, Calcineurin Activity
1016 Activation, Suppression of NFAT activation and hindrance of nuclear localization leads to Interference, nuclear localization of NFAT
1017 Interference, nuclear localization of NFAT leads to Reduction, NFAT/AP-1 complex formation
1508 Inhibition, Calcineurin Activity leads to Interference, nuclear localization of NFAT
1254 Inhibition, Calcineurin Activity leads to Suppression, IL-2 and IL-4 production
1015 Inhibition, Calcineurin Activity leads to Activation, Suppression of NFAT activation and hindrance of nuclear localization
1509 Reduction, NFAT/AP-1 complex formation leads to Suppression, IL-2 and IL-4 production
1256 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of production of cytotoxic T-cells
1257 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of T-cell dependent antibody production
1018 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression in mixed lymphocyte reaction (MLR)
1019 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of T-cell dependent antibody response (TDAR)
1020 Reduction, NFAT/AP-1 complex formation leads to Impairment, T-cell dependent antibody response
1021 Reduction, NFAT/AP-1 complex formation leads to Relief, Relief of atopic dermatitis
1022 Reduction, NFAT/AP-1 complex formation leads to Increase, Increased susceptibility to infection
1346 Decrease, Circulating ETH leads to Decrease, Circulating CCAP
1000 Decrease, Circulating ETH leads to Increase, Incomplete ecdysis
1008 Decrease, Circulating ETH leads to Decrease, Abdominal muscle contraction
1001 Decreased, synthesis and secretion of molting fluid proteases leads to Increase, Incomplete ecdysis
1190 Increase, Incomplete ecdysis leads to Increased, Mortality
1002 Increase, Incomplete ecdysis leads to Increase, Mortality
1010 Decrease, Abdominal muscle contraction leads to Increase, Incomplete ecdysis
1009 Decreased, Synthesis of molting fluid proteases leads to Decreased, Digestion of old cuticle
1011 Decreased, Digestion of old cuticle leads to Increase, Incomplete ecdysis
1023 Binding of antagonist, PPAR alpha leads to stabilization, PPAR alpha co-repressor
1024 stabilization, PPAR alpha co-repressor leads to Decreased, PPARalpha transactivation of gene expression
1026 Inhibition, Deiodinase 2 leads to Decreased, Triiodothyronine (T3) in serum
1042 Inhibition, Deiodinase 2 leads to Reduced, Posterior swim bladder inflation
1043 Inhibition, Deiodinase 2 leads to Reduced, Anterior swim bladder inflation
1199 Inhibition, Deiodinase 2 leads to Decreased, Triiodothyronine (T3) in tissues
1027 Decreased, Triiodothyronine (T3) in serum leads to Reduced, Posterior swim bladder inflation
1035 Decreased, Triiodothyronine (T3) in serum leads to Reduced, Anterior swim bladder inflation
1028 Reduced, Posterior swim bladder inflation leads to Reduced, Swimming performance
1031 Reduced, Posterior swim bladder inflation leads to Reduced, Anterior swim bladder inflation
1041 Reduced, Posterior swim bladder inflation leads to Reduced, Young of year survival
1029 Reduced, Swimming performance leads to Reduced, Young of year survival
1641 Reduced, Swimming performance leads to Growth, reduction
1642 Reduced, Swimming performance leads to Decreased, survival
1030 Reduced, Young of year survival leads to Decrease, Population trajectory
1032 Reduced, Anterior swim bladder inflation leads to Reduced, Hearing
1034 Reduced, Anterior swim bladder inflation leads to Reduced, Swimming performance
1033 Reduced, Hearing leads to Reduced, Young of year survival
1037 Inhibition, Deiodinase 1 leads to Decreased, Triiodothyronine (T3) in serum
1044 Inhibition, Deiodinase 1 leads to Reduced, Posterior swim bladder inflation
1045 Inhibition, Deiodinase 1 leads to Reduced, Anterior swim bladder inflation
1198 Inhibition, Deiodinase 1 leads to Decreased, Triiodothyronine (T3) in tissues
1047 Increased, Chloride influx leads to Increased, Inhibitory postsynaptic potential
1048 Increased, Inhibitory postsynaptic potential leads to Inhibition, Motor neuron activity
1054 Increased, Inhibitory postsynaptic potential leads to Induction, Somatic muscle paralysis
1058 Increased, Inhibitory postsynaptic potential leads to Induction, pharyngeal muscle paralysis
1049 Inhibition, Motor neuron activity leads to Induction, Somatic muscle paralysis
1050 Induction, Somatic muscle paralysis leads to Increased, Mortality
1055 Induction, Somatic muscle paralysis leads to Inhibition, Feeding
1053 Increased, Neuronal synaptic inhibition leads to Increased, Inhibitory postsynaptic potential
1056 Inhibition, Feeding leads to Increased, Mortality
1057 Activation, Glutamate-gated chloride channels leads to Increased, Chloride conductance
1059 Induction, pharyngeal muscle paralysis leads to Inhibition, Feeding
1063 Increased, induction of UDPGT's in liver leads to Increased, T4/T3 catabolism
1064 Increased, T4/T3 catabolism leads to Decreased, serum T4/T3
1065 Decreased, serum T4/T3 leads to Increased, Thyroid-stimulating hormone (TSH)
1066 Increased, Thyroid-stimulating hormone (TSH) leads to Increased, Hypertrophy and proliferation (follicular cell)
1067 Increased, Hypertrophy and proliferation (follicular cell) leads to Increased, Hyperplasia (follicular cells)
1068 Increased, Hyperplasia (follicular cells) leads to Increased Apoptosis, Adenomas/carcinomas (follicular cell)
1071 Activation of specific nuclear receptors, PPAR-gamma activation leads to Increased, adipogenesis
1072 Activation of specific nuclear receptors, PPAR-gamma activation leads to Increased, secretion of local growth factors
1609 Activation of specific nuclear receptors, PPAR-gamma activation leads to increased adipogenesis
1073 Increased, adipogenesis leads to Increased, secretion of local growth factors
1074 Increased, secretion of local growth factors leads to Increased, proliferation of mesenchymal cells
1075 Increased, secretion of local growth factors leads to Increased, IGF-1 (mouse)
1624 Increased, secretion of local growth factors leads to Differentiation of fibroblasts
1625 Increased, secretion of local growth factors leads to EMT
1129 Increased, secretion of local growth factors leads to Increased, Cell Proliferation (mesothelium)
1076 Increased, proliferation of mesenchymal cells leads to Increased, Firbrosarcoma
1077 Increased, proliferation of mesenchymal cells leads to Increased, liposarcoma
1078 Increased, proliferation of mesenchymal cells leads to Increased, hemagiosarcoma
1079 Activation, beta-2 adrenergic receptor leads to Increased activity, beta-2 adrenergic receptor
1080 Increased activity, beta-2 adrenergic receptor leads to relaxation, smooth muscle
1081 relaxation, smooth muscle leads to Proliferation/Clonal Expansion, smooth muscle
1082 Proliferation/Clonal Expansion, smooth muscle leads to Hypertrophy/hyperplasia, smooth muscle
1083 Hypertrophy/hyperplasia, smooth muscle leads to Promotion, mesovarian leiomyomas
1084 Decreased, Ovarian E2 leads to Increased, secretion of GnRH from hypothalamus
1085 Decreased, Ovarian E2 leads to Decrease, E2 blood concentrations at hypothalamus
1086 Suppression, Estrogen receptor (ER) activity leads to Decrease, E2 blood concentrations at hypothalamus
1088 Increased, secretion of GnRH from hypothalamus leads to Increased, secrection of FSH from anterior pituitary
1089 Increased, secretion of GnRH from hypothalamus leads to Increased, secretion of LH from anterior pituitary
1090 Increased, secrection of FSH from anterior pituitary leads to Hyperplasia, ovarian stromal cells
1091 Increased, secrection of FSH from anterior pituitary leads to Hyperplasia, ovarian epithelium
1092 Increased, secretion of LH from anterior pituitary leads to Hyperplasia, ovarian stromal cells
1094 Hyperplasia, ovarian stromal cells leads to Promotion, ovarian granular cell tumors
1093 Hyperplasia, ovarian epithelium leads to Promotion, ovarian adenomas
1087 Decrease, E2 blood concentrations at hypothalamus leads to Increased, secretion of GnRH from hypothalamus
1095 Increased, PPAR-alpha activation leads to Decreased, bile flow
1096 Increased, PPAR-alpha activation leads to Increased, cholestasis
1097 Increased, PPAR-alpha activation leads to Alteration, lipid metabolism
1101 Decreased, bile flow leads to Increased, cholestasis
1100 Increased, cholestasis leads to prolonged, elevation of serun CCK
1098 prolonged, elevation of serun CCK leads to Increased, Cellular proliferation / hyperplasia of acinar cells
1099 Increased, Cellular proliferation / hyperplasia of acinar cells leads to Increased, Pancreatic acinar tumors
1102 prepubertal increase, Estrogen receptor (ER) activity leads to Activation, estrogen receptor alpha
1103 Activation, estrogen receptor alpha leads to Promotion, SIX-1 postive basal-type progenitor cells
1104 Promotion, SIX-1 postive basal-type progenitor cells leads to Proliferation/Clonal Expansion, aberrant basal cells
1105 Proliferation/Clonal Expansion, aberrant basal cells leads to squamous metaplasia, aberrant basal cells
1106 squamous metaplasia, aberrant basal cells leads to Increased, Hyperplasia (glandular epithelial cells of endometrium)
1107 Increased, Hyperplasia (glandular epithelial cells of endometrium) leads to Increased, adenosquamous carcinomas of endometrium
1108 Decreased, GnRH pulsatility/release in hypothalamus leads to Decreased, LH Surge from anterior pituitary
1109 Decreased, LH Surge from anterior pituitary leads to interruption, Ovulation
1110 Decreased, LH Surge from anterior pituitary leads to prolonged, estrus
1118 interruption, Ovulation leads to Increased, circulating estrogen levels
1111 prolonged, estrus leads to Increased, circulating estrogen levels
1112 prolonged, estrus leads to Increased, prolactin exposure
1113 Increased, circulating estrogen levels leads to Hyperplasia, Mammary gland
1119 Increased, circulating estrogen levels leads to Increased, lactotroph hyperplasia and hypertrophy
1114 Increased, prolactin exposure leads to Hyperplasia, Mammary gland
1115 Hyperplasia, Mammary gland leads to Increased, latency period
1116 Hyperplasia, Mammary gland leads to Increased, Adenomas/carcinomas (mammary)
1117 Increased, latency period leads to Increased, Adenomas/carcinomas (mammary)
1120 Increased, lactotroph hyperplasia and hypertrophy leads to Increased, adenomas (pituitary)
1121 Decreased, Dopaminergic activity leads to Increased, prolactin secretion
1122 Increased, prolactin secretion leads to Increased, hyperplasia (mammary gland)
1123 Increased, hyperplasia (mammary gland) leads to Increased, latency period
1124 Increased, hyperplasia (mammary gland) leads to Increased, Adenomas/carcinomas (mammary)
1125 persistent, cytotoxicity (pleura or peritoneum) leads to Increased, inflammation
1126 persistent, cytotoxicity (pleura or peritoneum) leads to Increased, Oxidative Stress
1127 Increased, inflammation leads to Increased, secretion of local growth factors
1300 Increased, Oxidative Stress leads to Increase, DNA Damage
1128 Increased, Oxidative Stress leads to Increased, secretion of local growth factors
1160 Increased, Oxidative Stress leads to Occurrence, renal proximal tubular necrosis
1130 Increased, Cell Proliferation (mesothelium) leads to Increased, mesotheliomas
1142 Decreased, Thyroxine (T4) in tissues leads to Altered, Amphibian metamorphosis
1163 Decreased, Thyroxine (T4) in tissues leads to Decreased, Triiodothyronine (T3) in tissues
1132 Increased, blood uric acid concentration leads to Occurrence, tophi (urate) deposition
1158 Increased, blood uric acid concentration leads to Increased, Oxidative Stress
1134 Occurrence, renal proximal tubular necrosis leads to Increased, blood potassium concentration
1156 Occurrence, renal proximal tubular necrosis leads to Increased, blood uric acid concentration
1135 Increased, blood potassium concentration leads to Occurrence, cardiac arrthymia
1140 Increased, blood potassium concentration leads to Occurrence, cardiac arrhythmia
1136 Occurrence, cardiac arrthymia leads to Increased, Mortality
1133 Occurrence, tophi (urate) deposition leads to Occurrence, renal proximal tubular necrosis
1137 Inhibition, Cyclooxygenase 1 activity leads to Decreased, Prostaglandin F2alpha concentration, plasma
1138 Decreased, Prostaglandin F2alpha concentration, plasma leads to Occurrence, renal ischemia
1139 Occurrence, renal ischemia leads to Occurrence, renal proximal tubular necrosis
1159 Occurrence, renal ischemia leads to Increased, Oxidative Stress
1141 Occurrence, cardiac arrhythmia leads to Increased, Mortality
1145 Weakened, Colony leads to Death/Failure, Colony
1151 Abnormal, Role change within caste leads to Weakened, Colony
1155 Increased, Deformed Wing Virus levels leads to Weakened, Colony
1157 Increased, Energetic demands and therefore metabolic stress leads to Abnormal, Foraging activity and behavior
1161 Unknown, MIE leads to Increased, Reactive oxygen species
1162 Increased, Reactive oxygen species leads to Increased, Oxidative Stress
1696 Increased, Reactive oxygen species leads to increased, oncotic necrosis
1164 Decreased, Triiodothyronine (T3) in tissues leads to Altered, Amphibian metamorphosis
1168 Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur leads to Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)
1169 Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) leads to Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis
1165 Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo leads to Hemostasis, Depletion from blood of fully functional carboxylated clotting factors
1170 Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis leads to Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction
1166 Hemostasis, Depletion from blood of fully functional carboxylated clotting factors leads to Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur
1167 Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle leads to Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo
1171 Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction leads to Impaired recruitment , Population trajectory
1175 Increased, water retention in foot leads to Increased, foot detachment
1223 Increased, water retention in foot leads to Increased, valve movement
1182 Delayed, Sexual maturity leads to Decreased, Reproductive Success
1180 Decreased, Reproductive Success leads to Decline, Population
1501 Decreased, Reproductive Success leads to Decreased, Population trajectory
1320 Increased, valve movement leads to induced spawning
1334 Increased, valve movement leads to Induced parturition
1173 Increased, valve movement leads to Depletion, energy reserves
1174 Increased, valve movement leads to Increased, water retention in foot
1216 Increased, valve movement leads to Increased, water pumping
1227 Increased, valve movement leads to Increase, predation
1181 Depletion, energy reserves leads to Delayed, Sexual maturity
1185 Depletion, energy reserves leads to Increase, predation
1179 premature, spawning 1 leads to Decreased, Reproductive Success
1188 Decreased, gametogenesis leads to Decreased, Reproductive Success
1211 premature, Spawning leads to Increased, Population
1222 premature, Spawning leads to Decreased, Reproductive Success
1193 increased or inappropriate, mantel display leads to Decreased, Reproductive Success
1219 increased or inappropriate, mantel display leads to Depletion, energy reserves
1220 increased or inappropriate, mantel display leads to induced, parturition
1194 Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p leads to Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei
1195 Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei leads to Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp
1196 Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp leads to Osteoporosis and vascular calcification, Bone deterioration
1197 Inhibition, Iodotyrosine deiodinase (IYD) leads to Thyroidal Iodide, Decreased
1200 Inhibition, Deiodinase 3 leads to Increased, Triiodothyronine (T3) in tissues
1201 Increased, Triiodothyronine (T3) in tissues leads to Altered, Amphibian metamorphosis
1202 Inhibition, Pendrin leads to TH synthesis, Decreased
1203 Inhibition, Dual oxidase leads to TH synthesis, Decreased
1204 Activation, Hepatic nuclear receptor(s) leads to Increased, Hepatic thyroid hormone uptake/transport
1205 Activation, Hepatic nuclear receptor(s) leads to Induction, Upregulation of glucuronyltransferase activity
1206 Increased, Hepatic thyroid hormone uptake/transport leads to Increase, Biliary excretion TH glucuronide
1214 Increased, mantel display leads to Increased, Reproductive Success
1328 Increased, oocyte maturation leads to induced spawning
1213 Increased, oocyte maturation leads to Increased, Reproductive Success
1329 Increased, cilia movement leads to induced spawning
1210 Increased, cilia movement leads to premature, Spawning
1215 Increased, Reproductive Success leads to Increased, Population
1224 Increased, water pumping leads to Increased, water retention in foot
1225 Increased, water pumping leads to premature, Spawning
1226 Increased, water pumping leads to induced, parturition
1221 induced, parturition leads to Decreased, Reproductive Success
1230 modulation, Genes/proteins that regulate hepatocyte fate leads to Increase, Mitogenic cell proliferation (hepatocytes)
1231 modulation, Genes/proteins that regulate hepatocyte fate leads to Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
1232 Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci leads to Increase, Adenomas/carcinomas (hepatocellular)
1238 Increase activation, Nuclear factor kappa B (NF-kB) leads to modulation, Genes/proteins that regulate hepatocyte fate
1241 Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids leads to Peptide Oxidation
1360 Activation, NADPH Oxidase leads to ROS formation
1235 Activation, NADPH Oxidase leads to Peptide Oxidation
1234 Increase, Genes involved in fatty acid oxidation leads to Peptide Oxidation
1240 Increase, Genes involved in fatty acid oxidation leads to Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
1243 Decreased, sodium conductance 2 leads to Decreased, Ionotropic GABA receptor chloride channel conductance
1244 Decreased, sodium conductance 2 leads to Decreased, GABA release
1245 Decreased, GABA release leads to Decreased, Chloride conductance
1294 Activation, Estrogen receptor leads to Increased, Non-genomic signaling
1307 Activation, Estrogen receptor leads to Increased, Second Messenger Production
1246 Activation, Estrogen receptor leads to Increased, ER binding to DNA (classical pathway)
1249 Activation, Estrogen receptor leads to Increased, ER binding to T.F. to DNA (non-classical pathway)
1247 Increase, Cell Proliferation (Epithelial Cells) leads to Increased, Ductal Hyperplasia
1248 Decreased, Apoptosis (Epithelial Cells) leads to Increased, Ductal Hyperplasia
1296 Increased, ER binding to DNA (classical pathway) leads to Altered, Gene Expression
1250 Increased, ER binding to DNA (classical pathway) leads to Increase, Cell Proliferation (Epithelial Cells)
1297 Increased, ER binding to T.F. to DNA (non-classical pathway) leads to Altered, Gene Expression
1251 Increased, ER binding to T.F. to DNA (non-classical pathway) leads to Increase, Cell Proliferation (Epithelial Cells)
1266 Increased, Proliferation (Endothelial cells) leads to Increased, Angiogenesis
1267 Increased, Migration (Endothelial Cells) leads to Increased, Angiogenesis
1295 Increased, Non-genomic signaling leads to Increased, ER binding to T.F. to DNA (non-classical pathway)
1302 Increased, Non-genomic signaling leads to Altered, Gene Expression
1252 Increased, Ductal Hyperplasia leads to N/A, Breast Cancer
1301 Increase, DNA Damage leads to Altered, Gene Expression
1468 Increase, DNA Damage leads to Increase, Apoptosis
1253 Binding, Immunophilins leads to Inhibition, Calcineurin Activity
1510 Suppression, IL-2 and IL-4 production leads to Impairment, T-cell dependent antibody response
1255 Suppression, IL-2 and IL-4 production leads to Interference, nuclear localization of NFAT
1258 Suppression, Suppression of production of cytotoxic T-cells leads to Impairment, T-cell dependent antibody response
1260 Suppression, Suppression of production of cytotoxic T-cells leads to Increase, Increased susceptibility to infection
1259 Suppression, Suppression of T-cell dependent antibody production leads to Increase, Increased susceptibility to infection
1261 Activation, Juvenile hormone receptor leads to Induction, Doublesex1 gene
1262 Induction, Doublesex1 gene leads to Induction, Male reproductive tract
1264 Increased, Male offspring leads to Decline, Population
1263 Induction, Male reproductive tract leads to Increased, Male offspring
1269 Altered expression of hepatic CAR-dependent genes leads to Increase, Mitogenic cell proliferation (hepatocytes)
1284 TRPA1 activation, TRPA1 Receptor leads to Non-neuronal production of IL-8/CXCL1, Epithelial irritation
1576 TRPA1 activation, TRPA1 Receptor leads to Generation of novel epitopes , Antigen presentation
1271 TRPA1 activation, TRPA1 Receptor leads to Opening of calcium channel, Calcium influx
1273 Sensory Airway Irritation leads to Cough, Dyspnea, Sneezing, Acute respiratory effect
1280 Opening of calcium channel, Calcium influx leads to SP (Substance P) release, Local increase of SP
1272 Opening of calcium channel, Calcium influx leads to Sensory Airway Irritation
1274 Opening of calcium channel, Calcium influx leads to Excitation, Trigeminal nerve excitation
1575 Excitation, Trigeminal nerve excitation leads to SP (Substance P) release, Local increase of SP
1578 Excitation, Trigeminal nerve excitation leads to Increased CGRP
1582 Excitation, Trigeminal nerve excitation leads to Irritation induced sneezing
1583 Excitation, Trigeminal nerve excitation leads to Increased NKA
1275 Excitation, Trigeminal nerve excitation leads to Cough, Dyspnea, Sneezing, Acute respiratory effect
1276 Excitation, Trigeminal nerve excitation leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1574 SP (Substance P) release, Local increase of SP leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1577 SP (Substance P) release, Local increase of SP leads to Leukocyte infiltration
1772 SP (Substance P) release, Local increase of SP leads to Respiratory irritability
1279 SP (Substance P) release, Local increase of SP leads to Non-neuronal production of TNF, Epithelial irritation
1771 Increased Airway Hyper-responsiveness,Cough, Dyspnea leads to Respiratory irritability
1288 Non-neuronal production of TNF, Epithelial irritation leads to Opening of calcium channel, Calcium influx
1277 Non-neuronal production of TNF, Epithelial irritation leads to Leukocyte infiltration
1290 Leukocyte infiltration leads to Sensitization, Immune system
1278 Leukocyte infiltration leads to Respiratory irritability
1770 Respiratory irritability leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1281 TRPV1 activation, TRPV1 leads to Opening of calcium channel, Calcium influx
1282 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to TRPA1 activation, TRPA1 Receptor
1285 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to Generation of novel epitopes , Antigen presentation
1286 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to Production of nerve growth factor , Epithelial irritation
1283 Production of nerve growth factor , Epithelial irritation leads to SP (Substance P) release, Local increase of SP
1287 Non-neuronal production of IL-8/CXCL1, Epithelial irritation leads to Opening of calcium channel, Calcium influx
1289 Generation of novel epitopes , Antigen presentation leads to Sensitization, Immune system
1291 Oxidation leads to Generation of novel epitopes , Antigen presentation
1292 Oxidation leads to TRPA1 activation, TRPA1 Receptor
1293 Oxidation leads to Production of nerve growth factor , Epithelial irritation
1298 Altered, Gene Expression leads to Altered, Protein Production
1299 Altered, Protein Production leads to Increased, Oxidative Stress
1303 Altered, Protein Production leads to Increased, Proliferation (Endothelial cells)
1304 Altered, Protein Production leads to Decreased, Apoptosis (Epithelial Cells)
1305 Altered, Protein Production leads to Increased, Motility
1306 Increased, Motility leads to Increased, Invasion
1308 Increased, Second Messenger Production leads to Increased, Non-genomic signaling
1310 Altered, Ca2+-calmodulin activated signal transduction leads to Impairment, Learning and memory
1314 Chronic, Mucus hypersecretion leads to Decrease, Lung function
1330 DNA topoisomerase II “poisons” leads to MLL translocation
1634 DNA topoisomerase II “poisons” leads to DSB
1331 MLL translocation leads to IFL
1324 induced spawning leads to Decreased, Reproductive Success
1325 induced spawning leads to Increased, Reproductive Success
1322 increased mantel display leads to Induced parturition
1323 Induced parturition leads to Decreased, Reproductive Success
1326 Induced parturition leads to Increased, Reproductive Success
1338 Decompartmentalization leads to Mitochondrial impairment
1340 narcosis leads to Mitochondrial impairment
1339 Direct mitochondrial inhibition leads to Mitochondrial impairment
1341 Mitochondrial impairment leads to Apoptosis
1342 Mitochondrial impairment leads to Necrosis
1368 Apoptosis leads to Reproductive failure
1713 Apoptosis leads to testicular toxicity
1735 Apoptosis leads to spermatocyte depletion
1344 Increase, E75b expression leads to Increase, Ftz-f1 expression
1345 Increase, Ftz-f1 expression leads to Decrease, Circulating ETH
1347 Decrease, Circulating CCAP leads to Decrease, Ecdysis motoneuron bursts
1348 Decrease, Ecdysis motoneuron bursts leads to Decrease, Excitatory postsynaptic potential
1349 Decrease, Excitatory postsynaptic potential leads to Decrease, Abdominal muscle contraction
1351 Increase, COX-2 expression leads to Altered, Cardiovascular development/function
1353 Inactivation of PPARγ leads to Activation of TGF-β signaling
1354 Activation of TGF-β signaling leads to Differentiation of Myofibroblast
1355 Activation of TGF-β signaling leads to Expression of Collagen
1721 Activation of TGF-β signaling leads to Increase, Inflammation
1723 Activation of TGF-β signaling leads to EMT
1356 Differentiation of Myofibroblast leads to Production of α-smooth muscle actin
1357 Expression of Collagen leads to Collagen Deposition
1358 Production of α-smooth muscle actin leads to Lung fibrosis
1359 Collagen Deposition leads to Lung fibrosis
1628 Collagen Deposition leads to Accumulation, Collagen
1361 ROS formation leads to Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK
1362 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Increased, DNA Damage-Repair
1363 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Damaging, Mitochondria
1364 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Activation, HIF-1
1365 Activation, HIF-1 leads to Apoptosis
1366 Increased, DNA Damage-Repair leads to Apoptosis
1369 Activation, JAK/STAT pathway leads to Activation, TGF-beta pathway
1370 Activation, TGF-beta pathway leads to Reproductive failure
1371 Up Regulation, SREBF2 leads to Up Regulation, Unsaturated fatty acid
1372 Up Regulation, Unsaturated fatty acid leads to Perturbation of cholesterol
1373 Down Regulation, GSS and GSTs gene leads to Glutathione synthesis
1376 Down Regulation, GSS and GSTs gene leads to Glutathione homeostasis
1374 Glutathione synthesis leads to Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene
1375 Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene leads to Perturbation of cholesterol
1377 Perturbation of cholesterol leads to Hepatotoxicity
1378 Glutathione homeostasis leads to Hepatotoxicity
1380 Activation, JNK leads to Activation, FOXO
1381 Activation, FOXO leads to Inhibition, Wnt pathway
1382 Inhibition, Wnt pathway leads to Defect of Embryogenesis
1383 Defect of Embryogenesis leads to Reproductive failure
1390 Increase, insulin leads to Activation, insulin receptor
1391 Activation, insulin receptor leads to Activation, mTORC2
1392 Activation, mTORC2 leads to Activation, AKT
1393 Activation, mTORC2 leads to Activation, mTORC1
1394 Activation, AKT leads to Activation, SREBP-1
1398 Activation, AKT leads to Activation, mTORC1
1400 Activation, AKT leads to Activation, L-FABP
1395 Activation, mTORC1 leads to Activation, L-FABP
1396 Activation, mTORC1 leads to Activation, HSD17B4
1399 Activation, mTORC1 leads to Activation, SREBP-1
1397 Activation, SREBP-1 leads to Activation, FXR
1403 Activation, SREBP-1 leads to Activation, SCD-1
1401 Activation, L-FABP leads to Increase, cytosolic fatty acid
1423 Activation, L-FABP leads to demethylation, PPARg promoter
1411 Activation, HSD17B4 leads to Inhibition, Mitochondrial fatty acid beta-oxidation
1415 Activation, HSD17B4 leads to Induction, fatty acid beta-oxidation
1407 Activation, FXR leads to Activation, SHP
1408 Activation, FXR leads to Activation, PPARα
1693 Increase, cytosolic fatty acid leads to steatohepatitis
1694 Increase, cytosolic fatty acid leads to Increased, Liver Steatosis
1405 Increased, lipogenesis leads to Increase, cytosolic fatty acid
1413 Inhibition, LXR leads to Inhibition, PPAR alpha
1421 Activation, aPKC leads to Activation, SREBP-1
1418 Activation, PI3K leads to Activation, AKT
1419 Activation, PI3K leads to Activation, L-FABP
1420 Activation, PI3K leads to Activation, aPKC
1416 Induction, fatty acid beta-oxidation leads to Inhibition, Steatosis
1417 Induction, fatty acid beta-oxidation leads to Decrease, cytosolic fatty acid
1425 Activation, LRH-1 leads to Activation, FAS
1520 Inhibit, serotonin transporter activity leads to Decreased, serotonin transporter activity
1426 Decreased, serotonin transporter activity leads to Increased, intracellular sodium (Na+)
1427 Decreased, serotonin transporter activity leads to Increased, intracellular chloride (Cl-)
1428 Decreased, serotonin transporter activity leads to Decreased, extracellular Na+
1429 Decreased, serotonin transporter activity leads to Decreased, extracellular chloride (Cl-)
1430 Decreased, serotonin transporter activity leads to Increased, extracellular serotonin
1431 Decreased, serotonin transporter activity leads to Decreased, intracellular serotonin
1521 Increased, extracellular serotonin leads to Decreased, extracellular serotonin
1529 Increased, extracellular serotonin leads to Decreased, 5-HT3
1531 Increased, extracellular serotonin leads to Activation, 5-HT2A
1455 Increased, intracellular sodium (Na+) leads to Activated, voltage-gated sodium channel
1465 Increased, intracellular chloride (Cl-) leads to Inactive, membrane depolarization
1432 Decreased, intracellular serotonin leads to Decreased, packaged serotonin
1433 Decreased, packaged serotonin leads to Decreased, synaptic release
1434 Decreased, synaptic release leads to Decreased, extracellular serotonin
1445 Increased, 5-HT3 leads to Increased, seizure
1446 Inactivated, 5-HTR leads to Reduce expression, BDNF
1511 Inactivated, 5-HTR leads to Reduced, BDNF
1447 Reduce expression, BDNF leads to Decreased, neuroplasticity
1448 Decreased, neuroplasticity leads to Increased, agitation
1449 Decreased, neuroplasticity leads to Increased, depression
1450 Increase, cortisone leads to Activation, Glucocorticoid Receptor
1523 Reduced, BDNF leads to Decreased, neuroplasticity
1438 Activation, 5-HT2A leads to Activate, PLC
1439 Activate, PLC leads to Increase, inositol triphosphate
1440 Increase, inositol triphosphate leads to Increase, intracellular calcium
1441 Increase, intracellular calcium leads to Activate, calmodulin
1442 Activate, calmodulin leads to Increase, myosin light chain phosphorylation
1443 Increase, myosin light chain phosphorylation leads to Increase, vascular smooth muscle contraction
1444 Increase, vascular smooth muscle contraction leads to Increase, hypertension
1581 Increase, hypertension leads to Respiratory irritability
1550 Increased, seizure leads to Increased, epilepsy
1435 Decreased, extracellular serotonin leads to Increased, 5-HT3
1436 Decreased, extracellular serotonin leads to Inactivated, 5-HTR
1437 Decreased, extracellular serotonin leads to Activation, 5-HT2A
1519 Decreased, extracellular serotonin leads to Decreased, synaptic release
1460 Increase, seizure leads to Increased, epilepsy
1452 Activated, presynaptic neuron 1 leads to Increased, glutamate
1453 Increased, glutamate leads to Activated, NMDA receptor
1454 Activated, NMDA receptor leads to Increased, intracellular sodium (Na+)
1457 Activated, voltage-gated sodium channel leads to Activated, membrane depolarization
1456 Treat, carbamazepine leads to Inhibit, voltage-gated sodium channel
1458 Activated, membrane depolarization leads to Increased, hippocampal hyperdepolarization
1555 Increased, RDX dose leads to Reduced, GABA-A receptor activation
1463 Increased, RDX dose leads to Activate, GABA-A receptor
1464 Activate, GABA-A receptor leads to Increased, intracellular chloride (Cl-)
1461 Activate, presynaptic neuron 2 leads to Increase, GABA
1462 Increase, GABA leads to Activate, GABA-A receptor
1549 Increased, hippocampal hyperdepolarization leads to Increased, seizure
1459 Increased, hippocampal hyperdepolarization leads to Increase, seizure
1595 Increase, Excessive ROS generation leads to Increase, DNA Damage
1598 Increase, Excessive ROS generation leads to Increase, Lipid peroxidation
1466 Increase, Excessive ROS generation leads to Peptide Oxidation
1596 Increase, Apoptosis leads to Increase, Follicular atresia
1469 Increase, Apoptosis leads to Decrease, Oogenesis
1741 Increase, Apoptosis leads to Growth
1751 Increase, Apoptosis leads to Increase, Mortality
1470 Decrease, Oogenesis leads to Decrease, Ovulation
1752 Decrease, Oogenesis leads to Decrease, Fecundity
1480 Activation, PTGS-1 leads to Increase, platelet aggregation
1481 Activation, PTGS-1 leads to Increase, mucosal blood flow
1482 Activation, PTGS-1 leads to Increase, mucous
1483 Activation, PTGS-1 leads to Increase, bicarbonate
1478 Activation, PTGS-2 leads to Decrease, leukocyte adherence
1479 Activation, PTGS-2 leads to Increase, angiogenesis
1484 Increase, bicarbonate leads to Activate, mucosal defense
1485 Increase, mucous leads to Activate, mucosal defense
1486 Increase, mucosal blood flow leads to Activate, mucosal defense
1474 Increase, platelet aggregation leads to Inhibit, gastric ulcer formation
1473 Increase, angiogenesis leads to Inhibit, gastric ulcer formation
1477 Increase, leukocyte adherence leads to Activate, leukocyte
1476 Activate, leukocyte leads to Activated, gastric ulcer formation
1475 Activate, mucosal defense leads to Inhibit, gastric ulcer formation
1489 Increase, surfactant leads to Activate, mucosal defense
1547 Decrease, surfactant leads to Reduced, mucosal defense
1488 Activate, phospholipase leads to Decrease, surfactant
1487 Increase, ammonium (NH4+) leads to Decrease, surfactant
1493 CYP7B activity, inhibition leads to 7α-hydroxypregnenolone synthesis in the brain, decreased
1494 CYP7B activity, inhibition leads to Locomotor activity, decreased
1495 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Locomotor activity, decreased
1496 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Dopamine release in the brain, decreased
1498 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Sexual behavior, decreased
1497 Dopamine release in the brain, decreased leads to Locomotor activity, decreased
1502 Dopamine release in the brain, decreased leads to Sexual behavior, decreased
1500 Locomotor activity, decreased leads to Decreased, Reproductive Success
1499 Sexual behavior, decreased leads to Decreased, Reproductive Success
1512 Activation of Cyp2E1 in the liver leads to Oxidative Stress
1515 Activation of Cyp2E1 in the liver leads to Hepatocytotoxicity
1685 Oxidative Stress leads to Glutamate dyshomeostasis
1690 Oxidative Stress leads to N/A, Cell injury/death
1513 Oxidative Stress leads to Hepatocytotoxicity
1516 Oxidative Stress leads to Liver Cancer
1514 Hepatocytotoxicity leads to Hepatocellular Regenerative Proliferation
1517 Hepatocytotoxicity leads to Liver Cancer
1518 Hepatocellular Regenerative Proliferation leads to Liver Cancer
1522 Increased, glucocorticoid receptor activity leads to Reduced, BDNF
1524 Increased, serotonin transporter activity leads to Increased, intracellular serotonin
1528 Increased, serotonin transporter activity leads to Decreased, extracellular serotonin
1525 Increased, intracellular serotonin leads to Increased, packaged serotonin
1526 Increased, packaged serotonin leads to Increased, synaptic release
1527 Increased, synaptic release leads to Increased, extracellular serotonin
1530 Decreased, 5-HT3 leads to Increased, seizure
1537 Reduced, PTGS1 function leads to Decreased, mucous
1539 Reduced, PTGS1 function leads to Decreased, bicarbonate
1532 Reduced, PTGS1 function leads to Reduced, platelet aggregation
1534 Reduced, PTGS1 function leads to Decreased, mucosal blood flow
1533 Reduced, platelet aggregation leads to Activated, gastric ulcer formation
1535 Decreased, mucosal blood flow leads to Reduced, mucosal defense
1536 Reduced, mucosal defense leads to Activated, gastric ulcer formation
1548 Reduced, mucosal defense leads to Helicobacter pylori infection
1538 Decreased, mucous leads to Reduced, mucosal defense
1540 Decreased, bicarbonate leads to Reduced, mucosal defense
1541 Reduced, PTGS2 function leads to Decreased, angiogenesis
1543 Reduced, PTGS2 function leads to Increased, leukocyte adherence
1542 Decreased, angiogenesis leads to Activated, gastric ulcer formation
1544 Increased, leukocyte adherence leads to Increased, leukocyte activation
1545 Increased, leukocyte activation leads to Activated, gastric ulcer formation
1546 Helicobacter pylori infection leads to Increase, ammonium (NH4+)
1551 Reduced, presynaptic neuron 2 activity leads to Decreased, GABA
1552 Decreased, GABA leads to Reduced, GABA-A receptor activation
1553 Reduced, GABA-A receptor activation leads to Decreased, intracellular chloride
1554 Decreased, intracellular chloride leads to Activated, membrane depolarization
1556 NFE2/Nrf2 repression leads to Reduced, FXR activity
1557 Reduced, FXR activity leads to Reduced, SHP activity
1558 Reduced, SHP activity leads to Activated, LXR
1559 Activated, LXR leads to Reduced, PPARalpha
1560 Reduced, PPARalpha leads to Reduced, HSD17B4 activity
1561 Reduced, HSD17B4 activity leads to Reduced, fatty acid beta oxidation
1562 Reduced, fatty acid beta oxidation leads to Increased, steatosis
1563 Mu Opioid Receptor Agonism leads to Release of G Proteins
1564 Release of G Proteins leads to Opening of GIRK channels
1568 Release of G Proteins leads to Inhibition of Ca Channels
1565 Opening of GIRK channels leads to hyperpolarisation, neuron
1569 Inhibition of Ca Channels leads to Inhibition of neurotransmitter release
1570 Inhibition of neurotransmitter release leads to Analgesia
1573 Inhibition of neurotransmitter release leads to Anti-depressant Activity
1571 Serotonin 1A Receptor Agonism leads to Release of G Proteins
1579 Increased CGRP leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1580 Increased CGRP leads to Increase, hypertension
1586 Increased CGRP leads to Leukocyte infiltration
1587 Increased CGRP leads to Respiratory irritability
1774 Irritation induced sneezing leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1584 Increased NKA leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1585 Increased NKA leads to Leukocyte infiltration
1773 Increased NKA leads to Respiratory irritability
1588 Sensing of the stressor leads to Pro-inflammatory cytokines increased
1589 Pro-inflammatory cytokines increased leads to SAA production increased
1590 SAA production increased leads to HDL-SAA formation
1591 HDL-SAA formation leads to Systemic cholesterol increased
1593 HDL-SAA formation leads to Foam cell formation
1592 Systemic cholesterol increased leads to Foam cell formation
1594 Foam cell formation leads to Plaque progression
1597 Increase, Follicular atresia leads to Decrease, Oogenesis
1599 Increase, Lipid peroxidation leads to Increase, Uncoupling of OXPHOS
1600 Increase, Uncoupling of OXPHOS leads to Decrease, Mitochondrial ATP production
1610 activation of CEBPA leads to Activation of specific nuclear receptors, PPAR-gamma activation
1611 activation of CEBPA leads to increased adipogenesis
1612 increased adipogenesis leads to obesity
1614 decreased dopamine leads to decreased reward
1615 decreased reward leads to decreased DNA methylation of tyrosine hydroxylase
1616 decreased reward leads to decreased methylation of dopamine transporter promoter
1617 decreased reward leads to decreased dopamine
1618 decreased DNA methylation of tyrosine hydroxylase leads to obesity
1620 decreased DNA methylation of tyrosine hydroxylase leads to decreased dopamine
1619 decreased methylation of dopamine transporter promoter leads to obesity
1621 decreased methylation of dopamine transporter promoter leads to decreased dopamine
1613 chronic high fat diet leads to decreased dopamine
1622 Sustained inflammatory cytokine release leads to Increased, secretion of local growth factors
1633 Sustained inflammatory cytokine release leads to Differentiation of fibroblasts
1626 Differentiation of fibroblasts leads to Expression of Collagen
1654 Differentiation of fibroblasts leads to Accumulation, Collagen
1627 EMT leads to Expression of Collagen
1655 EMT leads to Accumulation, Collagen
1725 EMT leads to Lung fibrosis
1630 Cell damage sensing leads to Sustained inflammatory cytokine release
1631 Cell damage sensing leads to Increase, ROS production
1632 Cell damage sensing leads to Increased, secretion of local growth factors
1635 DSB leads to MLL translocation
1636 Thiol protein adducts leads to Inhibition of lysyl oxidase
1637 Inhibition of lysyl oxidase leads to Reduction of collagen crosslinking
1638 Reduction of collagen crosslinking leads to Weak collagen matrix
1639 Weak collagen matrix leads to Notochord malformation
1640 Notochord malformation leads to Reduced, Swimming performance
1651 TGFbeta1 activation leads to TGFbeta pathway activation
1652 TGFbeta pathway activation leads to Differentiation of fibroblasts
1653 TGFbeta pathway activation leads to EMT
1663 Increase, Uncoupling of photophosphorylation leads to Decrease, Chloroplast ATP production
1664 Decrease, Chloroplast ATP production leads to Decrease, Chlorophyll synthesis
1665 Decrease, Chlorophyll synthesis leads to Decrease, Light harvest capacity
1666 Decrease, Light harvest capacity leads to Decrease, Photosynthesis
1667 Decrease, Photosynthesis leads to Decrease, Glycolysis
1668 Decrease, Glycolysis leads to Decrease, OXPHOS
1738 Decrease, Glycolysis leads to Decrease, Mitochondrial ATP production
1669 Decrease, OXPHOS leads to Decrease, Mitochondrial ATP production
1671 Decrease, Leaf cell mitosis leads to Decrease, Leaf development
1672 Decrease, Leaf development leads to Increase, Growth inhibition
1673 Inhibition, mitochondrial DNA polymerase gamma (Pol gamma) leads to Depletion, mtDNA
1674 Depletion, mtDNA leads to Dysfunction, Mitochondria
1675 Dysfunction, Mitochondria leads to Increase, Cytotoxicity (renal tubular cell)
1681 Dysfunction, Mitochondria leads to Decrease, Mitochondrial ATP production
1677 Binding of substrate, endocytic receptor leads to Disturbance, Lysosomal function
1683 Binding, SH/SeH proteins involved in protection against oxidative stress leads to N/A, Mitochondrial dysfunction 1
1689 Binding, SH/SeH proteins involved in protection against oxidative stress leads to Oxidative Stress
1765 Binding, SH/SeH proteins involved in protection against oxidative stress leads to Protection against oxidative stress, decreased
1686 Glutamate dyshomeostasis leads to N/A, Cell injury/death
1691 Glutamate dyshomeostasis leads to Neuronal network function, Decreased
1692 Inhibition of fatty acid beta oxidation leads to Increase, cytosolic fatty acid
1697 increased, oncotic necrosis leads to steatohepatitis
1763 Tissue resident cell activation leads to Increased pro-inflammatory mediators
1719 Increased pro-inflammatory mediators leads to N/A, Cell injury/death
1764 Increased pro-inflammatory mediators leads to Activation, Stellate cells
1702 Interaction with the cell membrane leads to Increased proinflammatory mediators
1703 Increased proinflammatory mediators leads to Recruitment of inflammatory cells
1704 Recruitment of inflammatory cells leads to Loss of alveolar capillary membrane integrity
1705 Loss of alveolar capillary membrane integrity leads to Activation of Th2 cells
1706 Activation of Th2 cells leads to Increased cellular proliferation and differentiation
1707 Increased cellular proliferation and differentiation leads to Increased extracellular matrix deposition
1708 Increased extracellular matrix deposition leads to Pulmonary fibrosis
1709 Histone deacetylase inhibition leads to Histone acetylation, increase
1714 Histone deacetylase inhibition leads to p21 (CDKN1A) expression, increase
1715 Histone deacetylase inhibition leads to cell cycle, disrupted
1716 Histone deacetylase inhibition leads to Apoptosis
1717 Histone deacetylase inhibition leads to testicular toxicity
1710 Histone acetylation, increase leads to p21 (CDKN1A) expression, increase
1711 p21 (CDKN1A) expression, increase leads to cell cycle, disrupted
1712 cell cycle, disrupted leads to Apoptosis
1720 Activation of PPARγ leads to Increase, Inflammation
1726 CYP2E1 Activation leads to Oxidative Stress in Brain
1729 Protein Adduct Formation leads to Unfolded Prortein Response
1727 Oxidative Stress in Brain leads to Lipid Peroxidation
1730 Oxidative Stress in Brain leads to Unfolded Prortein Response
1728 Lipid Peroxidation leads to Protein Adduct Formation
1731 Lipid Peroxidation leads to General Apoptosis
1732 Unfolded Prortein Response leads to General Apoptosis
1733 General Apoptosis leads to Neurodegeneration
1734 spermatocyte depletion leads to testicular toxicity
1736 D1 protein blockage leads to PSII activity
1737 PSII activity leads to Decrease, Photosynthesis
1740 PSII activity leads to Increase, Excessive ROS generation
1742 Increase, CHS inhibition leads to Decrease, Cuticular chitin synthesis
1743 Decrease, Cuticular chitin synthesis leads to Increase, Premature molting
1744 Increase, Premature molting leads to Increase, Mortality
1745 Increase, SUR binding leads to Increase, Cell membrane depolarization
1747 Increase, Opening of voltage-dependent calcium channel leads to Decrease, Cuticular chitin synthesis
1746 Increase, Cell membrane depolarization leads to Increase, Opening of voltage-dependent calcium channel
1749 Fatty Acid Beta Oxidation, Decreased leads to Decreased, Ketogenesis (production of ketone bodies)
1755 Blockade, L-Type Calcium Channels leads to Decrease, Calcium currents
1756 Decrease, Calcium currents leads to Decrease, Calcium binding to Troponin C
1760 Decrease, Calcium currents leads to Disruption, Intracellular calcium mobilization
1757 Decrease, Calcium binding to Troponin C leads to Decrease, Cardiac contractility
1758 Decrease, Cardiac contractility leads to Decrease, Cardiac ejection fraction
1759 Decrease, Cardiac ejection fraction leads to Heart failure
1761 Disruption, Intracellular calcium mobilization leads to Disruption, Sarcomere assembly
1762 Disruption, Sarcomere assembly leads to Decrease, Cardiac contractility
1766 Protection against oxidative stress, decreased leads to Oxidative Stress